{"title":"VEGFA Protein: Target Overview, Research Applications, and Selection Guide","description":"","products":[{"product_id":"recombinant-pig-vascular-endothelial-growth-factor-a-vegfa-protein-his-blc-02361p","title":"Recombinant Pig Vascular Endothelial Growth Factor A (VEGFA) Protein (His)","description":"\u003cmeta charset=\"utf-8\"\u003e\u003ch3\u003eProduct Overview\u003c\/h3\u003e\u003ctable width=\"100%\"\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRecombinant Pig Vascular Endothelial Growth Factor A (VEGFA) Protein (His) is produced by our E.coli expression system. This is a full length protein.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eGreater than 90% as determined by SDS-PAGE.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eUniprotkb\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003ca rel=\"nofollow\" target=\"_blank\"\u003e           P49151          \u003c\/a\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Symbol\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eVEGFA\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSynonyms\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eVEGFA; VEGFVascular endothelial growth factor A; VEGF-A; Vascular permeability factor; VPF\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSpecies\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eSus scrofa (Pig)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression System\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eE.coli\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTag\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eN-6His\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Protein Sequence\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eAPMAEGDQKPHEVVKFMDVYQRSYCRPIETLVDIFQEYPDEIEYIFKPSCVPLMRCGGCCNDEGLECVPTEEFNITMQIMRIKPHQGQHIGEMSFLQHNKCECRPKKDRARQENPCGPCSERRKHLFVQDPQTCKCSCKNTDSRCKARQLELNERTCRCDKPRR\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression Range\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e27-190aa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eProtein Length\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eFull Length of Mature Protein\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eMol. Weight\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e23.2kDa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eResearch Area\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eOthers\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eForm\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLiquid or Lyophilized powder\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eBuffer\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLiquid form: default storage buffer is Tris\/PBS-based buffer, 5%-50% glycerol. Lyophilized powder form: the buffer before lyophilization is Tris\/PBS-based buffer, 6% Trehalose, pH 8.0.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e1. Store at -20°C\/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C\/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C\/-80°C.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eNotes\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRepeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e \u003ch3\u003eTarget Details\u003c\/h3\u003e\u003ctable width=\"100%\"\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Function\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eGrowth factor active in angiogenesis, vasculogenesis and endothelial cell growth. Induces endothelial cell proliferation, promotes cell migration, inhibits apoptosis and induces permeabilization of blood vessels. Binds to the FLT1\/VEGFR1 and KDR\/VEGFR2 receptors, heparan sulfate and heparin. Binding to NRP1 receptor initiates a signaling pathway needed for motor neuron axon guidance and cell body migration, including for the caudal migration of facial motor neurons from rhombomere 4 to rhombomere 6 during embryonic development.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSubcellular Location\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eSecreted.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eProtein Families\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003ePDGF\/VEGF growth factor family\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDatabase References\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003cdiv\u003e \u003cp\u003e           KEGG:           \u003ca rel=\"nofollow\"\u003e            ssc:397157           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           STRING:           \u003ca rel=\"nofollow\"\u003e            9823.ENSSSCP00000001845           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           UniGene:           \u003ca rel=\"nofollow\"\u003e             PMID:                        28139071            \u003c\/a\u003e  \u003c\/p\u003e\n\u003cli\u003e            It was concluded that VEGF and factor VIII are important growth factors associated with fetal development in pigs and are identified in all uterine segments.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28237345            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            results are consistent with a participation of (VEFG) in the regulation of the dynamics of oviductal fluid secretion and the oviduct contractibility            \u003ca rel=\"nofollow\"\u003e             PMID:                        28257866            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Here we demonstrate that VEGF-165 mediates MSC differentiation into ECs via VEGFR-2-dependent induction of Sox18, which ultimately coordinates the transcriptional upregulation of specific markers of the EC phenotype.            \u003ca rel=\"nofollow\"\u003e             PMID:                        25913202            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            VEGF was significantly downregulated 7 days after cryotherapy of the sclera and stayed at that level until day 14. It returned to baseline by day 21.            \u003ca rel=\"nofollow\"\u003e             PMID:                        25510786            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            VEGF production, blood vessel network and follicle remodeling are impaired by the antiprogesterone RU486.            \u003ca rel=\"nofollow\"\u003e             PMID:                        24756033            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            findings suggest that the augmented neovascular response seen with VEGF administration was through the VEGF-induced upregulation of Notch signaling.            \u003ca rel=\"nofollow\"\u003e             PMID:                        24366099            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            interleukin-1beta-induced vascular endothelial growth factor in airway smooth muscle cells            \u003ca rel=\"nofollow\"\u003e             PMID:                        24142467            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Upregulation of VEGF during hypoxia in chondrocyte is mediated partially through HIF-1alpha.            \u003ca rel=\"nofollow\"\u003e             PMID:                        22970342            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            data shows that members of the VEGF-VEGFR system are temporally and spatially well localized for playing key roles during umbilical cord formation and its intensive growth observed after day 75 of pregnancy            \u003ca rel=\"nofollow\"\u003e             PMID:                        20825582            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            cardiac-specific and hypoxia-induced coexpression of VEGF and Ang1 improves the perfusion and function of porcine MI heart through the induction of angiogenesis and cardiomyocyte proliferation            \u003ca rel=\"nofollow\"\u003e             PMID:                        21245320            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The mRNA for VEGFA was expressed in early developing and in maturing glomeruli.            \u003ca rel=\"nofollow\"\u003e             PMID:                        20713984            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Data show that subventricular zone neural stem cells express VEGF and all VEGF splice variants, VEGFR1, VEGFR2 and Neuropilin-1 and -2 mRNAs.            \u003ca rel=\"nofollow\"\u003e             PMID:                        20552272            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The earlier increase in VEGF protein and mRNA expression in the Meishan versus the Yorkshire conceptus may explain the previously reported increased vascularity and increased placental efficiency of this breed compared the Yorkshire breed.            \u003ca rel=\"nofollow\"\u003e             PMID:                        14998908            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Contrast media did not affect bone marrow cell viability\/VEGF secretion.            \u003ca rel=\"nofollow\"\u003e             PMID:                        15274157            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            VEGF upregulation in the proliferative zone after ischemic damage may play a role in stimulating vascular invasion and granulation tissue formation in the necrotic hypertrophic zone of the epiphyseal cartilage            \u003ca rel=\"nofollow\"\u003e             PMID:                        15537448            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Data demonstrate that lipopolysaccharides evoke a heat shock response, with an increase heat shock proteins 70 and Hsp32) and of VEGF, a specific endothelial cell growth factor.            \u003ca rel=\"nofollow\"\u003e             PMID:                        16333987            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Vascular endothelial growth factor (VEGF) plays an important role in the thecal angiogenesis during follicular development.            \u003ca rel=\"nofollow\"\u003e             PMID:                        16372043            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            number of preovulatory follicles and the capillary density in the theca interna increased significantly in the ovaries injected with VEGF gene            \u003ca rel=\"nofollow\"\u003e             PMID:                        16538032            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            our study revealed the presence of VEGF in endothelial and smooth muscle cells of vascular subovarian plexus arteries            \u003ca rel=\"nofollow\"\u003e             PMID:                        16584087            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Differential regulation of VEGF isoforms may suggest specific physiological roles for some of them, particularly in angioregression occurring during the apoptotic structural luteolysis.            \u003ca rel=\"nofollow\"\u003e             PMID:                        16967516            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            VEGF ligand-receptor system may play an important role in the development and maintenance of the corpus luteum in pigs.            \u003ca rel=\"nofollow\"\u003e             PMID:                        17120307            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Sanguinarine inhibited both VEGF production and VEGF-induced Akt activation in swine granulosa cells.            \u003ca rel=\"nofollow\"\u003e             PMID:                        17310078            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            VEGF\/Flk-1\/Flt-1 system is activated during myocardial ischemia reperfusion injury.            \u003ca rel=\"nofollow\"\u003e             PMID:                        17868880            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            VEGF-A family members are probably involved in appropriate preparation of endometrium for implantation and in vascular events during implantation in pigs.            \u003ca rel=\"nofollow\"\u003e             PMID:                        17874446            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Hemodialysis graft placement leads to early increases in wall shear stress, VEGF-A, pro-MMP-9, MMP-2, VEGFR-1, VEGFR-2, and TIMP-1, which may contribute to the development of venous stenosis.            \u003ca rel=\"nofollow\"\u003e             PMID:                        18326810            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Interaction of soluble factors in plasma possibly generated during PICSO are not responsible for upregulation of HO-1 and VEGF mRNA.            \u003ca rel=\"nofollow\"\u003e             PMID:                        19618599            \u003c\/a\u003e \u003c\/li\u003e \u003c\/div\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"20ug","offer_id":43998593548513,"sku":"BLC-02361P","price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/products\/CSB-EP025833PI-SDS.jpg?v=1690501395"},{"product_id":"recombinant-rabbit-vascular-endothelial-growth-factor-a-vegfa-protein-his-blc-04184p","title":"Recombinant Rabbit Vascular Endothelial Growth Factor A (VEGFA) Protein (His)","description":"\u003cmeta charset=\"utf-8\"\u003e\u003ch3\u003eProduct Overview\u003c\/h3\u003e\u003ctable width=\"100%\"\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRecombinant Rabbit Vascular Endothelial Growth Factor A (VEGFA) Protein (His) is produced by our Yeast expression system. This is a full length protein.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eGreater than 90% as determined by SDS-PAGE.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eUniprotkb\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003ca rel=\"nofollow\" target=\"_blank\"\u003e           XP_002714743.1          \u003c\/a\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Symbol\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eVEGFA\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSpecies\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eOryctolagus cuniculus (Rabbit)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression System\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eYeast\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTag\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eN-6His\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Protein Sequence\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eYLWLLHAPLLHVSLDSLVAAFSVVFEVLPSSLDIPGSKKEEQASTQLGGVEEEHEASGVVTRQLAFVVDAITNPTLEKETKTITRIHKAPKFPSHFGFWKRAEEERGGKSSGEKSRKTDGVGERAQAGEQREGPGQRAAALTDRQTDTAPSPSAHLLPGRRPTVDAAASGGQQPEPAPEGGVEGVGARGIALKLFVQLLGCSRSGGVVVRAGGAEPSGAARSVSSGREEPPPPPPEEEGEEEGEKEEERGPRWRLGAGEPGSWTGEAAVCADSAPAARAPQALARASAPGARGARGGAEESGPSRSPSRRGSASRAGPGRASETMNFLLSWVHWSLALLLYLHHAKWSQAAPMAEEGDNKPHEVVKFMEVYRRSYCQPIETLVDIFQEYPDEIEYIFKPSCVPLVRCGGCCNDESLECVPTEEFNVTMQIMRIKPHQGQHIGEMSFLQHNKCECRCDKPRR\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression Range\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e51-511aa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eProtein Length\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eFull Length of Mature Protein\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eMol. Weight\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e51.7kDa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eResearch Area\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eOthers\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eForm\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLiquid or Lyophilized powder\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eBuffer\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLiquid form: default storage buffer is Tris\/PBS-based buffer, 5%-50% glycerol. Lyophilized powder form: the buffer before lyophilization is Tris\/PBS-based buffer, 6% Trehalose, pH 8.0.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e1. Store at -20°C\/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C\/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C\/-80°C.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eNotes\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRepeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"20ug","offer_id":43998804902113,"sku":"BLC-04184P","price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/products\/CSB-YP025833RB-SDS.jpg?v=1690507131"},{"product_id":"recombinant-rabbit-vascular-endothelial-growth-factor-a-vegfa-protein-his-sumo-blc-04483p","title":"Recombinant Rabbit Vascular Endothelial Growth Factor A (VEGFA) Protein (His-SUMO)","description":"\u003cmeta charset=\"utf-8\"\u003e\u003ch3\u003eProduct Overview\u003c\/h3\u003e\u003ctable width=\"100%\"\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRecombinant Rabbit Vascular Endothelial Growth Factor A (VEGFA) Protein (His-SUMO) is produced by our E.coli expression system. This is a full length protein.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eGreater than 90% as determined by SDS-PAGE.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eUniprotkb\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003ca rel=\"nofollow\" target=\"_blank\"\u003e           XP_002714743.1          \u003c\/a\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Symbol\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eVEGFA\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSpecies\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eOryctolagus cuniculus (Rabbit)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression System\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eE.coli\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTag\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eN-6His-SUMO\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Protein Sequence\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eYLWLLHAPLLHVSLDSLVAAFSVVFEVLPSSLDIPGSKKEEQASTQLGGVEEEHEASGVVTRQLAFVVDAITNPTLEKETKTITRIHKAPKFPSHFGFWKRAEEERGGKSSGEKSRKTDGVGERAQAGEQREGPGQRAAALTDRQTDTAPSPSAHLLPGRRPTVDAAASGGQQPEPAPEGGVEGVGARGIALKLFVQLLGCSRSGGVVVRAGGAEPSGAARSVSSGREEPPPPPPEEEGEEEGEKEEERGPRWRLGAGEPGSWTGEAAVCADSAPAARAPQALARASAPGARGARGGAEESGPSRSPSRRGSASRAGPGRASETMNFLLSWVHWSLALLLYLHHAKWSQAAPMAEEGDNKPHEVVKFMEVYRRSYCQPIETLVDIFQEYPDEIEYIFKPSCVPLVRCGGCCNDESLECVPTEEFNVTMQIMRIKPHQGQHIGEMSFLQHNKCECRCDKPRR\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression Range\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e51-511aa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eProtein Length\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eFull Length of Mature Protein\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eMol. Weight\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e65.7kDa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eResearch Area\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eOthers\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eForm\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLiquid or Lyophilized powder\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eBuffer\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLiquid form: default storage buffer is Tris\/PBS-based buffer, 5%-50% glycerol. Lyophilized powder form: the buffer before lyophilization is Tris\/PBS-based buffer, 6% Trehalose, pH 8.0.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e1. Store at -20°C\/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C\/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C\/-80°C.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eNotes\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRepeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"20ug","offer_id":43998827970785,"sku":"BLC-04483P","price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/products\/CSB-EP025833RB-SDS.jpg?v=1690508029"},{"product_id":"recombinant-human-vascular-endothelial-growth-factor-a-protein-vegfa-active-blc-06012p","title":"Recombinant Human Vascular Endothelial Growth Factor A Protein (VEGFA), Active","description":"\u003cmeta charset=\"utf-8\"\u003e\u003ch3\u003eProduct Overview\u003c\/h3\u003e\u003ctable width=\"100%\"\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRecombinant Human Vascular Endothelial Growth Factor A Protein (VEGFA), Active is produced by our Yeast expression system. This is a protein fragment.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eGreater than 97% as determined by SDS-PAGE and HPLC.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eEndotoxin\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLess than 1.0 EU\/μg as determined by LAL method.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eActivity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eFully biologically active when compared to standard. The ED50 as determined by a cell proliferation assay using human umbilical vein endothelial cells(HUVEC) is between 1.0-8.0 ng\/ml.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eUniprotkb\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003ca rel=\"nofollow\" target=\"_blank\"\u003e           P15692          \u003c\/a\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Symbol\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eVEGFA\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSynonyms\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eglioma-derived endothelial cell mitogen; MGC70609; MVCD1; Vascular endothelial growth factor A; Vascular Endothelial Growth Factor; Vascular permeability factor; VEGF; VEGF-A; VEGF165; Vegfa; VEGFA_HUMAN; VPF\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSpecies\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eHomo sapiens (Human)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression System\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eYeast\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTag\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eTag-Free\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eComplete Sequence\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eM+APMAEGGGQ NHHEVVKFMD VYQRSYCHPI ETLVDIFQEY PDEIEYIFKP SCVPLMRCGG CCNDEGLECV PTEESNITMQ IMRIKPHQGQ HIGEMSFLQH NKCECRPKKD RARQENPCGP CSERRKHLFV QDPQTCKCSC KNTDSRCKAR QLELNERTCR CDKPRR\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression Range\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e27-191aa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eProtein Length\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003ePartial of Isoform VEGF165\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eMol. Weight\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e19.3 kDa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eResearch Area\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eCancer\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eForm\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized powder\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eBuffer\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized from a 0.2 µm filtered PBS, pH 7.4, with 0.02 Tween-20\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eReconstitution\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eBriefly centrifuged the vial prior to opening to bring the contents to the bottom. Reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg\/mL. It is recommended to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C\/-80°C. The default final concentration of glycerol is 50%.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e1. Store at -20°C\/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C\/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C\/-80°C.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eNotes\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRepeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e \u003ch3\u003eTarget Details\u003c\/h3\u003e\u003ctable width=\"100%\"\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Function\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eGrowth factor active in angiogenesis, vasculogenesis and endothelial cell growth. Induces endothelial cell proliferation, promotes cell migration, inhibits apoptosis and induces permeabilization of blood vessels. Binds to the FLT1\/VEGFR1 and KDR\/VEGFR2 receptors, heparan sulfate and heparin. NRP1\/Neuropilin-1 binds isoforms VEGF-165 and VEGF-145. Isoform VEGF165B binds to KDR but does not activate downstream signaling pathways, does not activate angiogenesis and inhibits tumor growth. Binding to NRP1 receptor initiates a signaling pathway needed for motor neuron axon guidance and cell body migration, including for the caudal migration of facial motor neurons from rhombomere 4 to rhombomere 6 during embryonic development.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSubcellular Location\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eSecreted. Note=VEGF121 is acidic and freely secreted. VEGF165 is more basic, has heparin-binding properties and, although a significant proportion remains cell-associated, most is freely secreted. VEGF189 is very basic, it is cell-associated after secretion and is bound avidly by heparin and the extracellular matrix, although it may be released as a soluble form by heparin, heparinase or plasmin.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eProtein Families\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003ePDGF\/VEGF growth factor family\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDatabase References\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003cdiv\u003e \u003cp\u003e           HGNC:           \u003ca rel=\"nofollow\"\u003e            12680           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           OMIM:           \u003ca rel=\"nofollow\"\u003e            192240           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           KEGG:           \u003ca rel=\"nofollow\"\u003e            hsa:7422           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           STRING:           \u003ca rel=\"nofollow\"\u003e            9606.ENSP00000361125           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           UniGene:           \u003ca rel=\"nofollow\"\u003e             PMID:                        29386057            \u003c\/a\u003e  \u003c\/p\u003e\n\u003cli\u003e            VEGF and IL-8 play a prominent role in the pathogenesis of early forms of rosacea and the hemostasis system.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29578433            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The Novel Short Isoform of Securin Stimulates the Expression of Cyclin D3 and Angiogenesis Factors VEGFA and FGF2, but Does Not Affect the Expression of MYC Transcription Factor            \u003ca rel=\"nofollow\"\u003e             PMID:                        29989583            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            these results show peripheral blood levels of VEGF are significantly increased in colorectal patients            \u003ca rel=\"nofollow\"\u003e             PMID:                        29924680            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Study found that VEGF-A expression in the epidermis associated to the mechanism of facial reddened skin.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28677138            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Quantitative analysis of VEGF-121 isoform in the plasma of patients with recurrent glioblastoma could be a promising predictor of response to anti-angiogenetic treatment.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29747600            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Study evaluated for the first time the plasma levels and the diagnostic usefulness of VEGF, MMP-9, and TIMP-1 in cervical cancer (CC), not only independently but especially in combination with established cervical tumor markers. All tested parameters showed statistical significance when compared their concentrations in patients with CC to healthy women.            \u003ca rel=\"nofollow\"\u003e             PMID:                        30037277            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Results showed that VEGF expression level was upregulated in gallbladder cancer (GBC) tissues and cell lines under a hypoxic condition.            \u003ca rel=\"nofollow\"\u003e             PMID:                        30272364            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            these results indicate that sFlt-1 up-regulation by VEGF may be mediated by the VEGF\/Flt-1 and\/or VEGF\/KDR signaling pathways.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29497919            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            lncRNA TDRG1 may promote endometrial carcinoma cell proliferation and invasion by positively targeting VEGF-A and modulating relative genes.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29920344            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The data of this study indicated that the L-VEGF144 protein is not only a novel nucleolus protein but is likely to act as a mitogen to induce the proliferation of cancer cells.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29909500            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Study shows that vascular endothelial growth factor A stimulates STAT3 activity via nitrosylation of myocardin to regulate the expression of vascular smooth muscle cell differentiation markers.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28572685            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            There is no association between the studied VEGF-A single nucleotide variations and the responses to intravitreal ranibizumab therapy in diabetic macular edema. However, the VEGF-A rs833069 gene polymorphism has a clear association with the severity of diabetic retinopathy.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29030794            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            None of the investigated VEGF-A gene polymorphisms was found to be an independent prognostic marker for infantile hemangioma. However, there is evidence that individuals carrying at least one G allele of +405 G\/C VEGF-A polymorphism have significantly lower risk of IH.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29984822            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            This study showed that CIC haplotype of VEGF gene may be important risk factor for urothelial bladder cancer development in Tunisia.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29959793            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            FABP5 promotes tumor angiogenesis via activation of the IL6\/STAT3\/VEGFA signaling pathway in hepatocellular carcinoma.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29957468            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            This study did not identify a different VEGF 936CT genotype profile for patients with CHM who undergo SR versus those who progress to gestational trophoblastic neoplasia. However, the, results do suggest that this polymor- phism may affect susceptibility to complete hydatidiform-mole. Larger groups may improve the results of assessments of the predictive parameters of gestational trophoblastic neoplasia.            \u003ca rel=\"nofollow\"\u003e             PMID:                        30383950            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            there may be an association between rs6993770 polymorphism of VEGF and Metabolic Syndrome            \u003ca rel=\"nofollow\"\u003e             PMID:                        29891039            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The data supports the assumption that C9 gene expression may stimulate the expression of inflammatory (NLRP3) and angiogenic growth factors (VEGF) in retinal pigment epithelial cells.            \u003ca rel=\"nofollow\"\u003e             PMID:                        30090015            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            DEC2 could upregulate retinal VEGF gene expression through modulation of HIF1alpha levels under hypoxic conditions.            \u003ca rel=\"nofollow\"\u003e             PMID:                        30250985            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            High expression of VEGF is associated with Oral Invasive Carcinomas.            \u003ca rel=\"nofollow\"\u003e             PMID:                        30049191            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            High VEGF expression is associated with angiogenesis of esophageal squamous cell carcinoma.            \u003ca rel=\"nofollow\"\u003e             PMID:                        30015941            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            VEGF-A was over-expressed in hypoxic glioblastoma-derived exosomes, which enhance the permeability of a blood-brain barrier in vitro model by interrupting the expression of claudin-5 and occludin.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29787762            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Single CpG methylation appears to enhance VEGF G4 thermostability in a manner dependent on both the CpG methylation site and cation type            \u003ca rel=\"nofollow\"\u003e             PMID:                        29940278            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            shear stress was able to induce arterial endothelial differentiation of stem cells from human exfoliated deciduous teeth, and VEGF-DLL4\/NotchEphrinB2 signaling was involved in this process.            \u003ca rel=\"nofollow\"\u003e             PMID:                        30015843            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Data indicate that CD147 promotes breast cancer cell proliferation, metastasis, and invasion by modulating matrix metalloproteinase 9 (MMP-9) and vascular endothelial growth factor (VEGF) expression.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29901696            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Our data demonstrated that the expression of VEGF was significantly related to the tumor incidence, metastasis and prognosis of patients with gastric cancer, which provides new leads to the diagnosis of gastric cancer.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29914006            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            High VEGFA expression is associated with increased lymphangiogenesis and lymph node metastasis in prostate adenocarcinoma.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29544697            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            VEGF\/PKD-1 signaling axis increases angiogenic and arteriogenic gene expression. These studies suggest that the axis may regulate arteriolar differentiation through changing microvascular endothelial cells gene expression.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29380239            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            widely stained in sclerosing stromal tumours of the ovary            \u003ca rel=\"nofollow\"\u003e             PMID:                        29433373            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Study shows how vascular endothelial growth factor regulates protein kinase CbetaII (PKCbeta) promoter function in chronic lymphocytic leukaemia cells, stimulating PKCbeta gene transcription via increased association of SP1 and decreased association of STAT3.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28233872            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Our study suggests that VEGF kinetics is a prognostic factor for locally advanced esophageal squamous cell carcinoma patients receiving curative concurrent chemoradiotherapy. For these patients, lower post-treatment VEGF levels and decreasing levels of VEGF during CCRT are significantly associated with better clinical outcomes.            \u003ca rel=\"nofollow\"\u003e             PMID:                        30126380            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            These results suggest that DMBT can inhibit CNV by down-regulation of VEGF in retina through Akt\/NF-kappaB\/HIF-1alpha and ERK\/Nrf2\/HO-1\/HIF-1alpha pathway. DMBT might be a promising lead molecule for anti-CNV and serve as a therapeutic agent to inhibit CNV.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29446046            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            the expression of MMIF, HIF-1alpha, and VEGF in the serum and endometrial tissues may be used to assess the stage of endometriosis and the severity of dysmenorrhea.            \u003ca rel=\"nofollow\"\u003e             PMID:                        30074218            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            H3K27me3 and VEGF expression are both significantly associated with overall survival of synovial sarcoma, and H3K27me3 is a significant independent prognostic indicator in patients with synovial sarcoma            \u003ca rel=\"nofollow\"\u003e             PMID:                        29803658            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Study showed evidence that the VEGF rs699947 polymorphism was obviously associated with an increased risk of bladder cancer and renal cell carcinoma, particularly in Asian population, while no significant association was observed in overall urologic neoplasms. [review]            \u003ca rel=\"nofollow\"\u003e             PMID:                        30195633            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Low VEGFA expression is associated with Breast Cancer.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28744693            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            these findings indicated that miR655 may inhibit epithelial ovarian cancer (EOC)cell proliferation and invasion by repressing VEGF. Thus, the miR655\/VEGF pathway could serve as a novel therapeutic target for patients with EOC.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29845206            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The VEGF protein expression in gastric cancer tissues is positively correlated with TNM staging and lymph node metastasis in patients. The preoperative prediction results of MRI are well consistent with postoperative pathological results, and MRI features are correlated with lymph node metastasis in patients, which has an important guiding significance for the diagnosis and treatment of gastric cancer.            \u003ca rel=\"nofollow\"\u003e             PMID:                        30010108            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            ADM was an upstream molecule of HIF-1alpha\/VEGF and it promoted angiogenesis through upregulating HIF-1alpha\/VEGF in epithelial ovarian cancer.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28091613            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The expression of VEGF was negatively correlated with miR1.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29845255            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            EDF1 is required for VEGF-induced activation of the transcriptional activity of PPARgamma in HUVEC cells.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29933613            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Studied vascular endothelial growth factor A (VEGFA) gene +936T\/C single nucleotide polymorphism; found it has no significant correlation with biliary atresia in the Southern Chinese Han population.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29251369            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            miR125 targeted and inhibited the expression of VEGF through target sites located in the 3' untranslated region of VEGF mRNA.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29693153            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            higher levels of IL-6 and VEGF-A were significantly associated with shorter progression free survival in epithelial ovarian cancer            \u003ca rel=\"nofollow\"\u003e             PMID:                        29572186            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            results suggest that PEDF act as a multipotent factor in the skin and the imbalance of PEDF and VEGF may be responsible for the transformation from normal skin to psoriasis.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29579411            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            RTPCR analysis revealed that the expression levels of COX2 and VEGF were downregulated following morusin treatment... morusin significantly inhibited the proliferation of the lung cancer cell line A549, and may have affected the invasion and migration of the cells by downregulating the expression of tumor angiogenesisrelated genes.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29749480            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            These results suggest that VM formation is increased by EBVLMP1 via VEGF\/VEGFR1 signaling and provide additional information to clarify the role of EBVLMP1 in nasopharyngeal carcinoma (NPC)pathophysiology            \u003ca rel=\"nofollow\"\u003e             PMID:                        29749553            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Data suggest that expression of mRNA for ghrelin and VEGFA are up-regulated in endometrium of women with recurrent miscarriage; thus, ghrelin and VEGFA may play roles in pathogenesis of recurrent miscarriage. These case-control studies were conducted with endometrial tissue obtained during secretory phase of menstrual cycle. (VEGFA = vascular endothelial growth factor A)            \u003ca rel=\"nofollow\"\u003e             PMID:                        29221937            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            AEG-1 was found to be significantly associated with hypoxia in ovarian cancer by regulating the HIF-1alpha\/NF-kappaB\/VEGF pathway.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29770329            \u003c\/a\u003e \u003c\/li\u003e \u003c\/div\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"10ug","offer_id":43998989320417,"sku":"BLC-06012P","price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/products\/CSB-AP002591HU.jpg?v=1690512637"},{"product_id":"recombinant-human-vascular-endothelial-growth-factor-a-protein-vegfa-active-blc-06018p","title":"Recombinant Human Vascular Endothelial Growth Factor A Protein (VEGFA), Active","description":"\u003cmeta charset=\"utf-8\"\u003e\u003ch3\u003eProduct Overview\u003c\/h3\u003e\u003ctable width=\"100%\"\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRecombinant Human Vascular Endothelial Growth Factor A Protein (VEGFA), Active is produced by our E.coli expression system. This is a full length protein.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eGreater than 95% as determined by SDS-PAGE and HPLC.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eEndotoxin\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLess than 1.0 EU\/μg as determined by LAL method.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eActivity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eFully biologically active when compared to standard. The ED50 as determined by a cell proliferation assay using human umbilical vein endothelial cells(HUVEC) is between 1.0-8.0 ng\/ml.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eUniprotkb\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003ca rel=\"nofollow\" target=\"_blank\"\u003e           P15692          \u003c\/a\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Symbol\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eVEGFA\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSynonyms\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eglioma-derived endothelial cell mitogen; MGC70609; MVCD1; Vascular endothelial growth factor A; Vascular Endothelial Growth Factor; Vascular permeability factor; VEGF; VEGF-A; VEGF165; Vegfa; VEGFA_HUMAN; VPF\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSpecies\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eHomo sapiens (Human)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression System\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eE.Coli\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTag\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eTag-Free\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eComplete Sequence\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eM+APMAEGGGQ NHHEVVKFMD VYQRSYCHPI ETLVDIFQEY PDEIEYIFKP SCVPLMRCGG CCNDEGLECV PTEESNITMQ IMRIKPHQGQ HIGEMSFLQH NKCECRPKKD RARQENPCGP CSERRKHLFV QDPQTCKCSC KNTDSRCKAR QLELNERTCR CDKPRR\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression Range\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e27-191aa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eProtein Length\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eFull Length of Isoform VEGF165\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eMol. Weight\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e19.3 kDa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eResearch Area\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eCancer\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eForm\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized powder\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eBuffer\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized from a 0.2 µm filtered PBS, pH 7.4\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eReconstitution\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eBriefly centrifuged the vial prior to opening to bring the contents to the bottom. Reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg\/mL. It is recommended to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C\/-80°C. The default final concentration of glycerol is 50%.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e1. Store at -20°C\/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C\/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C\/-80°C.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eNotes\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRepeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e \u003ch3\u003eTarget Details\u003c\/h3\u003e\u003ctable width=\"100%\"\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Function\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eGrowth factor active in angiogenesis, vasculogenesis and endothelial cell growth. Induces endothelial cell proliferation, promotes cell migration, inhibits apoptosis and induces permeabilization of blood vessels. Binds to the FLT1\/VEGFR1 and KDR\/VEGFR2 receptors, heparan sulfate and heparin. NRP1\/Neuropilin-1 binds isoforms VEGF-165 and VEGF-145. Isoform VEGF165B binds to KDR but does not activate downstream signaling pathways, does not activate angiogenesis and inhibits tumor growth. Binding to NRP1 receptor initiates a signaling pathway needed for motor neuron axon guidance and cell body migration, including for the caudal migration of facial motor neurons from rhombomere 4 to rhombomere 6 during embryonic development.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSubcellular Location\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eSecreted. Note=VEGF121 is acidic and freely secreted. VEGF165 is more basic, has heparin-binding properties and, although a significant proportion remains cell-associated, most is freely secreted. VEGF189 is very basic, it is cell-associated after secretion and is bound avidly by heparin and the extracellular matrix, although it may be released as a soluble form by heparin, heparinase or plasmin.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eProtein Families\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003ePDGF\/VEGF growth factor family\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDatabase References\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003cdiv\u003e \u003cp\u003e           HGNC:           \u003ca rel=\"nofollow\"\u003e            12680           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           OMIM:           \u003ca rel=\"nofollow\"\u003e            192240           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           KEGG:           \u003ca rel=\"nofollow\"\u003e            hsa:7422           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           STRING:           \u003ca rel=\"nofollow\"\u003e            9606.ENSP00000361125           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           UniGene:           \u003ca rel=\"nofollow\"\u003e             PMID:                        29386057            \u003c\/a\u003e  \u003c\/p\u003e\n\u003cli\u003e            VEGF and IL-8 play a prominent role in the pathogenesis of early forms of rosacea and the hemostasis system.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29578433            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The Novel Short Isoform of Securin Stimulates the Expression of Cyclin D3 and Angiogenesis Factors VEGFA and FGF2, but Does Not Affect the Expression of MYC Transcription Factor            \u003ca rel=\"nofollow\"\u003e             PMID:                        29989583            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            these results show peripheral blood levels of VEGF are significantly increased in colorectal patients            \u003ca rel=\"nofollow\"\u003e             PMID:                        29924680            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Study found that VEGF-A expression in the epidermis associated to the mechanism of facial reddened skin.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28677138            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Quantitative analysis of VEGF-121 isoform in the plasma of patients with recurrent glioblastoma could be a promising predictor of response to anti-angiogenetic treatment.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29747600            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Study evaluated for the first time the plasma levels and the diagnostic usefulness of VEGF, MMP-9, and TIMP-1 in cervical cancer (CC), not only independently but especially in combination with established cervical tumor markers. All tested parameters showed statistical significance when compared their concentrations in patients with CC to healthy women.            \u003ca rel=\"nofollow\"\u003e             PMID:                        30037277            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Results showed that VEGF expression level was upregulated in gallbladder cancer (GBC) tissues and cell lines under a hypoxic condition.            \u003ca rel=\"nofollow\"\u003e             PMID:                        30272364            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            these results indicate that sFlt-1 up-regulation by VEGF may be mediated by the VEGF\/Flt-1 and\/or VEGF\/KDR signaling pathways.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29497919            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            lncRNA TDRG1 may promote endometrial carcinoma cell proliferation and invasion by positively targeting VEGF-A and modulating relative genes.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29920344            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The data of this study indicated that the L-VEGF144 protein is not only a novel nucleolus protein but is likely to act as a mitogen to induce the proliferation of cancer cells.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29909500            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Study shows that vascular endothelial growth factor A stimulates STAT3 activity via nitrosylation of myocardin to regulate the expression of vascular smooth muscle cell differentiation markers.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28572685            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            There is no association between the studied VEGF-A single nucleotide variations and the responses to intravitreal ranibizumab therapy in diabetic macular edema. However, the VEGF-A rs833069 gene polymorphism has a clear association with the severity of diabetic retinopathy.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29030794            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            None of the investigated VEGF-A gene polymorphisms was found to be an independent prognostic marker for infantile hemangioma. However, there is evidence that individuals carrying at least one G allele of +405 G\/C VEGF-A polymorphism have significantly lower risk of IH.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29984822            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            This study showed that CIC haplotype of VEGF gene may be important risk factor for urothelial bladder cancer development in Tunisia.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29959793            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            FABP5 promotes tumor angiogenesis via activation of the IL6\/STAT3\/VEGFA signaling pathway in hepatocellular carcinoma.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29957468            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            This study did not identify a different VEGF 936CT genotype profile for patients with CHM who undergo SR versus those who progress to gestational trophoblastic neoplasia. However, the, results do suggest that this polymor- phism may affect susceptibility to complete hydatidiform-mole. Larger groups may improve the results of assessments of the predictive parameters of gestational trophoblastic neoplasia.            \u003ca rel=\"nofollow\"\u003e             PMID:                        30383950            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            there may be an association between rs6993770 polymorphism of VEGF and Metabolic Syndrome            \u003ca rel=\"nofollow\"\u003e             PMID:                        29891039            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The data supports the assumption that C9 gene expression may stimulate the expression of inflammatory (NLRP3) and angiogenic growth factors (VEGF) in retinal pigment epithelial cells.            \u003ca rel=\"nofollow\"\u003e             PMID:                        30090015            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            DEC2 could upregulate retinal VEGF gene expression through modulation of HIF1alpha levels under hypoxic conditions.            \u003ca rel=\"nofollow\"\u003e             PMID:                        30250985            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            High expression of VEGF is associated with Oral Invasive Carcinomas.            \u003ca rel=\"nofollow\"\u003e             PMID:                        30049191            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            High VEGF expression is associated with angiogenesis of esophageal squamous cell carcinoma.            \u003ca rel=\"nofollow\"\u003e             PMID:                        30015941            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            VEGF-A was over-expressed in hypoxic glioblastoma-derived exosomes, which enhance the permeability of a blood-brain barrier in vitro model by interrupting the expression of claudin-5 and occludin.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29787762            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Single CpG methylation appears to enhance VEGF G4 thermostability in a manner dependent on both the CpG methylation site and cation type            \u003ca rel=\"nofollow\"\u003e             PMID:                        29940278            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            shear stress was able to induce arterial endothelial differentiation of stem cells from human exfoliated deciduous teeth, and VEGF-DLL4\/NotchEphrinB2 signaling was involved in this process.            \u003ca rel=\"nofollow\"\u003e             PMID:                        30015843            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Data indicate that CD147 promotes breast cancer cell proliferation, metastasis, and invasion by modulating matrix metalloproteinase 9 (MMP-9) and vascular endothelial growth factor (VEGF) expression.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29901696            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Our data demonstrated that the expression of VEGF was significantly related to the tumor incidence, metastasis and prognosis of patients with gastric cancer, which provides new leads to the diagnosis of gastric cancer.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29914006            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            High VEGFA expression is associated with increased lymphangiogenesis and lymph node metastasis in prostate adenocarcinoma.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29544697            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            VEGF\/PKD-1 signaling axis increases angiogenic and arteriogenic gene expression. These studies suggest that the axis may regulate arteriolar differentiation through changing microvascular endothelial cells gene expression.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29380239            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            widely stained in sclerosing stromal tumours of the ovary            \u003ca rel=\"nofollow\"\u003e             PMID:                        29433373            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Study shows how vascular endothelial growth factor regulates protein kinase CbetaII (PKCbeta) promoter function in chronic lymphocytic leukaemia cells, stimulating PKCbeta gene transcription via increased association of SP1 and decreased association of STAT3.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28233872            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Our study suggests that VEGF kinetics is a prognostic factor for locally advanced esophageal squamous cell carcinoma patients receiving curative concurrent chemoradiotherapy. For these patients, lower post-treatment VEGF levels and decreasing levels of VEGF during CCRT are significantly associated with better clinical outcomes.            \u003ca rel=\"nofollow\"\u003e             PMID:                        30126380            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            These results suggest that DMBT can inhibit CNV by down-regulation of VEGF in retina through Akt\/NF-kappaB\/HIF-1alpha and ERK\/Nrf2\/HO-1\/HIF-1alpha pathway. DMBT might be a promising lead molecule for anti-CNV and serve as a therapeutic agent to inhibit CNV.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29446046            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            the expression of MMIF, HIF-1alpha, and VEGF in the serum and endometrial tissues may be used to assess the stage of endometriosis and the severity of dysmenorrhea.            \u003ca rel=\"nofollow\"\u003e             PMID:                        30074218            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            H3K27me3 and VEGF expression are both significantly associated with overall survival of synovial sarcoma, and H3K27me3 is a significant independent prognostic indicator in patients with synovial sarcoma            \u003ca rel=\"nofollow\"\u003e             PMID:                        29803658            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Study showed evidence that the VEGF rs699947 polymorphism was obviously associated with an increased risk of bladder cancer and renal cell carcinoma, particularly in Asian population, while no significant association was observed in overall urologic neoplasms. [review]            \u003ca rel=\"nofollow\"\u003e             PMID:                        30195633            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Low VEGFA expression is associated with Breast Cancer.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28744693            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            these findings indicated that miR655 may inhibit epithelial ovarian cancer (EOC)cell proliferation and invasion by repressing VEGF. Thus, the miR655\/VEGF pathway could serve as a novel therapeutic target for patients with EOC.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29845206            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The VEGF protein expression in gastric cancer tissues is positively correlated with TNM staging and lymph node metastasis in patients. The preoperative prediction results of MRI are well consistent with postoperative pathological results, and MRI features are correlated with lymph node metastasis in patients, which has an important guiding significance for the diagnosis and treatment of gastric cancer.            \u003ca rel=\"nofollow\"\u003e             PMID:                        30010108            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            ADM was an upstream molecule of HIF-1alpha\/VEGF and it promoted angiogenesis through upregulating HIF-1alpha\/VEGF in epithelial ovarian cancer.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28091613            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The expression of VEGF was negatively correlated with miR1.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29845255            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            EDF1 is required for VEGF-induced activation of the transcriptional activity of PPARgamma in HUVEC cells.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29933613            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Studied vascular endothelial growth factor A (VEGFA) gene +936T\/C single nucleotide polymorphism; found it has no significant correlation with biliary atresia in the Southern Chinese Han population.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29251369            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            miR125 targeted and inhibited the expression of VEGF through target sites located in the 3' untranslated region of VEGF mRNA.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29693153            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            higher levels of IL-6 and VEGF-A were significantly associated with shorter progression free survival in epithelial ovarian cancer            \u003ca rel=\"nofollow\"\u003e             PMID:                        29572186            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            results suggest that PEDF act as a multipotent factor in the skin and the imbalance of PEDF and VEGF may be responsible for the transformation from normal skin to psoriasis.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29579411            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            RTPCR analysis revealed that the expression levels of COX2 and VEGF were downregulated following morusin treatment... morusin significantly inhibited the proliferation of the lung cancer cell line A549, and may have affected the invasion and migration of the cells by downregulating the expression of tumor angiogenesisrelated genes.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29749480            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            These results suggest that VM formation is increased by EBVLMP1 via VEGF\/VEGFR1 signaling and provide additional information to clarify the role of EBVLMP1 in nasopharyngeal carcinoma (NPC)pathophysiology            \u003ca rel=\"nofollow\"\u003e             PMID:                        29749553            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Data suggest that expression of mRNA for ghrelin and VEGFA are up-regulated in endometrium of women with recurrent miscarriage; thus, ghrelin and VEGFA may play roles in pathogenesis of recurrent miscarriage. These case-control studies were conducted with endometrial tissue obtained during secretory phase of menstrual cycle. (VEGFA = vascular endothelial growth factor A)            \u003ca rel=\"nofollow\"\u003e             PMID:                        29221937            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            AEG-1 was found to be significantly associated with hypoxia in ovarian cancer by regulating the HIF-1alpha\/NF-kappaB\/VEGF pathway.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29770329            \u003c\/a\u003e \u003c\/li\u003e \u003c\/div\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"10ug","offer_id":43998989910241,"sku":"BLC-06018P","price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/products\/CSB-AP002601HU.jpg?v=1690512655"},{"product_id":"recombinant-horse-vascular-endothelial-growth-factor-a-vegfa-protein-his-myc-blc-06545p","title":"Recombinant Horse Vascular Endothelial Growth Factor A (VEGFA) Protein (His\u0026Myc)","description":"\u003cmeta charset=\"utf-8\"\u003e\u003ch3\u003eProduct Overview\u003c\/h3\u003e\u003ctable width=\"100%\"\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRecombinant Horse Vascular Endothelial Growth Factor A (VEGFA) Protein (His\u0026amp;Myc) is produced by our E.coli expression system. This is a full length protein.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eGreater than 90% as determined by SDS-PAGE.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eUniprotkb\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003ca rel=\"nofollow\" target=\"_blank\"\u003e           Q9GKR0          \u003c\/a\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Symbol\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eVEGFA\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSpecies\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eEquus caballus (Horse)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression System\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eE.coli\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTag\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eN-10His\u0026amp;C-Myc\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Protein Sequence\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eAPMAEGEHKTHEVVKFMDVYQRSYCRPIETLVDIFQEYPDEIEYIFKPSCVPLMRCGGCCNDEGLECVPTAEFNITMQIMRIKPHQSQHIGEMSFLQHSKCECRPKKDKARQENPCGPCSERRKHLFVQDPQTCKCSCKNTDSRCKARQLELNERTCRCDKPRR\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression Range\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e27-190aa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eProtein Length\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eFull Length of Mature Protein\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eMol. Weight\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e26.6 kDa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eResearch Area\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eCancer\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eForm\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLiquid or Lyophilized powder\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eBuffer\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLiquid form: default storage buffer is Tris\/PBS-based buffer, 5%-50% glycerol. Lyophilized powder form: the buffer before lyophilization is Tris\/PBS-based buffer, 6% Trehalose, pH 8.0.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eReconstitution\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eBriefly centrifuged the vial prior to opening to bring the contents to the bottom. Reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg\/mL. It is recommended to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C\/-80°C. The default final concentration of glycerol is 50%.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e1. Store at -20°C\/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C\/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C\/-80°C.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eNotes\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRepeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e \u003ch3\u003eTarget Details\u003c\/h3\u003e\u003ctable width=\"100%\"\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Function\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eGrowth factor active in angiogenesis, vasculogenesis and endothelial cell growth. Induces endothelial cell proliferation, promotes cell migration, inhibits apoptosis and induces permeabilization of blood vessels. Binds to the FLT1\/VEGFR1 and KDR\/VEGFR2 receptors, heparan sulfate and heparin. Binding to NRP1 receptor initiates a signaling pathway needed for motor neuron axon guidance and cell body migration, including for the caudal migration of facial motor neurons from rhombomere 4 to rhombomere 6 during embryonic development.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSubcellular Location\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eSecreted.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eProtein Families\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003ePDGF\/VEGF growth factor family\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDatabase References\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003cdiv\u003e \u003cp\u003e           KEGG:           \u003ca rel=\"nofollow\"\u003e            ecb:100033839           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           UniGene:           \u003ca rel=\"nofollow\"\u003e             PMID:                        25313202            \u003c\/a\u003e  \u003c\/p\u003e\n\u003cli\u003e            TNF may up-regulate VEGF and stimulate angiogenesis in the mare early corpus luteum.            \u003ca rel=\"nofollow\"\u003e             PMID:                        22492973            \u003c\/a\u003e \u003c\/li\u003e \u003c\/div\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"20ug","offer_id":43999052300513,"sku":"BLC-06545P","price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/products\/CSB-EP025833HO-SDS.jpg?v=1690514570"},{"product_id":"recombinant-human-vascular-endothelial-growth-factor-a-vegfa-protein-his-blc-07867p","title":"Recombinant Human Vascular Endothelial Growth Factor A (VEGFA) Protein (His)","description":"\u003cmeta charset=\"utf-8\"\u003e\u003ch3\u003eProduct Overview\u003c\/h3\u003e\u003ctable width=\"100%\"\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRecombinant Human Vascular Endothelial Growth Factor A (VEGFA) Protein (His) is produced by our Yeast expression system. This is a full length protein.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eGreater than 90% as determined by SDS-PAGE.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eUniprotkb\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003ca rel=\"nofollow\" target=\"_blank\"\u003e           P15692          \u003c\/a\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Symbol\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eVEGFA\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSpecies\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eHomo sapiens (Human)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression System\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eYeast\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTag\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eN-6His\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Protein Sequence\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eAPMAEGGGQNHHEVVKFMDVYQRSYCHPIETLVDIFQEYPDEIEYIFKPSCVPLMRCGGCCNDEGLECVPTEESNITMQIMRIKPHQGQHIGEMSFLQHNKCECRPKKDRARQEKKSVRGKGKGQKRKRKKSRYKSWSVYVGARCCLMPWSLPGPHPCGPCSERRKHLFVQDPQTCKCSCKNTDSRCKARQLELNERTCRCDKPRR\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression Range\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e27-232aa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eProtein Length\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eFull length\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eMol. Weight\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e25.9 kDa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eResearch Area\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eCancer\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eForm\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLiquid or Lyophilized powder\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eBuffer\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLiquid form: default storage buffer is Tris\/PBS-based buffer, 5%-50% glycerol. Lyophilized powder form: the buffer before lyophilization is Tris\/PBS-based buffer, 6% Trehalose, pH 8.0.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eReconstitution\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eBriefly centrifuged the vial prior to opening to bring the contents to the bottom. Reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg\/mL. It is recommended to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C\/-80°C. The default final concentration of glycerol is 50%.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e1. Store at -20°C\/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C\/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C\/-80°C.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eNotes\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRepeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e \u003ch3\u003eTarget Details\u003c\/h3\u003e\u003ctable width=\"100%\"\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Function\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eGrowth factor active in angiogenesis, vasculogenesis and endothelial cell growth. Induces endothelial cell proliferation, promotes cell migration, inhibits apoptosis and induces permeabilization of blood vessels. Binds to the FLT1\/VEGFR1 and KDR\/VEGFR2 receptors, heparan sulfate and heparin. NRP1\/Neuropilin-1 binds isoforms VEGF-165 and VEGF-145. Isoform VEGF165B binds to KDR but does not activate downstream signaling pathways, does not activate angiogenesis and inhibits tumor growth. Binding to NRP1 receptor initiates a signaling pathway needed for motor neuron axon guidance and cell body migration, including for the caudal migration of facial motor neurons from rhombomere 4 to rhombomere 6 during embryonic development.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSubcellular Location\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eSecreted. Note=VEGF121 is acidic and freely secreted. VEGF165 is more basic, has heparin-binding properties and, although a significant proportion remains cell-associated, most is freely secreted. VEGF189 is very basic, it is cell-associated after secretion and is bound avidly by heparin and the extracellular matrix, although it may be released as a soluble form by heparin, heparinase or plasmin.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eProtein Families\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003ePDGF\/VEGF growth factor family\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDatabase References\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003cdiv\u003e \u003cp\u003e           HGNC:           \u003ca rel=\"nofollow\"\u003e            12680           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           OMIM:           \u003ca rel=\"nofollow\"\u003e            192240           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           KEGG:           \u003ca rel=\"nofollow\"\u003e            hsa:7422           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           STRING:           \u003ca rel=\"nofollow\"\u003e            9606.ENSP00000361125           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           UniGene:           \u003ca rel=\"nofollow\"\u003e             PMID:                        29386057            \u003c\/a\u003e  \u003c\/p\u003e\n\u003cli\u003e            VEGF and IL-8 play a prominent role in the pathogenesis of early forms of rosacea and the hemostasis system.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29578433            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The Novel Short Isoform of Securin Stimulates the Expression of Cyclin D3 and Angiogenesis Factors VEGFA and FGF2, but Does Not Affect the Expression of MYC Transcription Factor            \u003ca rel=\"nofollow\"\u003e             PMID:                        29989583            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            these results show peripheral blood levels of VEGF are significantly increased in colorectal patients            \u003ca rel=\"nofollow\"\u003e             PMID:                        29924680            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Study found that VEGF-A expression in the epidermis associated to the mechanism of facial reddened skin.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28677138            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Quantitative analysis of VEGF-121 isoform in the plasma of patients with recurrent glioblastoma could be a promising predictor of response to anti-angiogenetic treatment.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29747600            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Study evaluated for the first time the plasma levels and the diagnostic usefulness of VEGF, MMP-9, and TIMP-1 in cervical cancer (CC), not only independently but especially in combination with established cervical tumor markers. All tested parameters showed statistical significance when compared their concentrations in patients with CC to healthy women.            \u003ca rel=\"nofollow\"\u003e             PMID:                        30037277            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Results showed that VEGF expression level was upregulated in gallbladder cancer (GBC) tissues and cell lines under a hypoxic condition.            \u003ca rel=\"nofollow\"\u003e             PMID:                        30272364            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            these results indicate that sFlt-1 up-regulation by VEGF may be mediated by the VEGF\/Flt-1 and\/or VEGF\/KDR signaling pathways.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29497919            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            lncRNA TDRG1 may promote endometrial carcinoma cell proliferation and invasion by positively targeting VEGF-A and modulating relative genes.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29920344            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The data of this study indicated that the L-VEGF144 protein is not only a novel nucleolus protein but is likely to act as a mitogen to induce the proliferation of cancer cells.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29909500            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Study shows that vascular endothelial growth factor A stimulates STAT3 activity via nitrosylation of myocardin to regulate the expression of vascular smooth muscle cell differentiation markers.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28572685            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            There is no association between the studied VEGF-A single nucleotide variations and the responses to intravitreal ranibizumab therapy in diabetic macular edema. However, the VEGF-A rs833069 gene polymorphism has a clear association with the severity of diabetic retinopathy.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29030794            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            None of the investigated VEGF-A gene polymorphisms was found to be an independent prognostic marker for infantile hemangioma. However, there is evidence that individuals carrying at least one G allele of +405 G\/C VEGF-A polymorphism have significantly lower risk of IH.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29984822            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            This study showed that CIC haplotype of VEGF gene may be important risk factor for urothelial bladder cancer development in Tunisia.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29959793            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            FABP5 promotes tumor angiogenesis via activation of the IL6\/STAT3\/VEGFA signaling pathway in hepatocellular carcinoma.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29957468            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            This study did not identify a different VEGF 936CT genotype profile for patients with CHM who undergo SR versus those who progress to gestational trophoblastic neoplasia. However, the, results do suggest that this polymor- phism may affect susceptibility to complete hydatidiform-mole. Larger groups may improve the results of assessments of the predictive parameters of gestational trophoblastic neoplasia.            \u003ca rel=\"nofollow\"\u003e             PMID:                        30383950            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            there may be an association between rs6993770 polymorphism of VEGF and Metabolic Syndrome            \u003ca rel=\"nofollow\"\u003e             PMID:                        29891039            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The data supports the assumption that C9 gene expression may stimulate the expression of inflammatory (NLRP3) and angiogenic growth factors (VEGF) in retinal pigment epithelial cells.            \u003ca rel=\"nofollow\"\u003e             PMID:                        30090015            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            DEC2 could upregulate retinal VEGF gene expression through modulation of HIF1alpha levels under hypoxic conditions.            \u003ca rel=\"nofollow\"\u003e             PMID:                        30250985            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            High expression of VEGF is associated with Oral Invasive Carcinomas.            \u003ca rel=\"nofollow\"\u003e             PMID:                        30049191            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            High VEGF expression is associated with angiogenesis of esophageal squamous cell carcinoma.            \u003ca rel=\"nofollow\"\u003e             PMID:                        30015941            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            VEGF-A was over-expressed in hypoxic glioblastoma-derived exosomes, which enhance the permeability of a blood-brain barrier in vitro model by interrupting the expression of claudin-5 and occludin.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29787762            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Single CpG methylation appears to enhance VEGF G4 thermostability in a manner dependent on both the CpG methylation site and cation type            \u003ca rel=\"nofollow\"\u003e             PMID:                        29940278            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            shear stress was able to induce arterial endothelial differentiation of stem cells from human exfoliated deciduous teeth, and VEGF-DLL4\/NotchEphrinB2 signaling was involved in this process.            \u003ca rel=\"nofollow\"\u003e             PMID:                        30015843            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Data indicate that CD147 promotes breast cancer cell proliferation, metastasis, and invasion by modulating matrix metalloproteinase 9 (MMP-9) and vascular endothelial growth factor (VEGF) expression.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29901696            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Our data demonstrated that the expression of VEGF was significantly related to the tumor incidence, metastasis and prognosis of patients with gastric cancer, which provides new leads to the diagnosis of gastric cancer.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29914006            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            High VEGFA expression is associated with increased lymphangiogenesis and lymph node metastasis in prostate adenocarcinoma.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29544697            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            VEGF\/PKD-1 signaling axis increases angiogenic and arteriogenic gene expression. These studies suggest that the axis may regulate arteriolar differentiation through changing microvascular endothelial cells gene expression.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29380239            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            widely stained in sclerosing stromal tumours of the ovary            \u003ca rel=\"nofollow\"\u003e             PMID:                        29433373            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Study shows how vascular endothelial growth factor regulates protein kinase CbetaII (PKCbeta) promoter function in chronic lymphocytic leukaemia cells, stimulating PKCbeta gene transcription via increased association of SP1 and decreased association of STAT3.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28233872            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Our study suggests that VEGF kinetics is a prognostic factor for locally advanced esophageal squamous cell carcinoma patients receiving curative concurrent chemoradiotherapy. For these patients, lower post-treatment VEGF levels and decreasing levels of VEGF during CCRT are significantly associated with better clinical outcomes.            \u003ca rel=\"nofollow\"\u003e             PMID:                        30126380            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            These results suggest that DMBT can inhibit CNV by down-regulation of VEGF in retina through Akt\/NF-kappaB\/HIF-1alpha and ERK\/Nrf2\/HO-1\/HIF-1alpha pathway. DMBT might be a promising lead molecule for anti-CNV and serve as a therapeutic agent to inhibit CNV.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29446046            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            the expression of MMIF, HIF-1alpha, and VEGF in the serum and endometrial tissues may be used to assess the stage of endometriosis and the severity of dysmenorrhea.            \u003ca rel=\"nofollow\"\u003e             PMID:                        30074218            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            H3K27me3 and VEGF expression are both significantly associated with overall survival of synovial sarcoma, and H3K27me3 is a significant independent prognostic indicator in patients with synovial sarcoma            \u003ca rel=\"nofollow\"\u003e             PMID:                        29803658            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Study showed evidence that the VEGF rs699947 polymorphism was obviously associated with an increased risk of bladder cancer and renal cell carcinoma, particularly in Asian population, while no significant association was observed in overall urologic neoplasms. [review]            \u003ca rel=\"nofollow\"\u003e             PMID:                        30195633            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Low VEGFA expression is associated with Breast Cancer.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28744693            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            these findings indicated that miR655 may inhibit epithelial ovarian cancer (EOC)cell proliferation and invasion by repressing VEGF. Thus, the miR655\/VEGF pathway could serve as a novel therapeutic target for patients with EOC.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29845206            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The VEGF protein expression in gastric cancer tissues is positively correlated with TNM staging and lymph node metastasis in patients. The preoperative prediction results of MRI are well consistent with postoperative pathological results, and MRI features are correlated with lymph node metastasis in patients, which has an important guiding significance for the diagnosis and treatment of gastric cancer.            \u003ca rel=\"nofollow\"\u003e             PMID:                        30010108            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            ADM was an upstream molecule of HIF-1alpha\/VEGF and it promoted angiogenesis through upregulating HIF-1alpha\/VEGF in epithelial ovarian cancer.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28091613            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The expression of VEGF was negatively correlated with miR1.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29845255            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            EDF1 is required for VEGF-induced activation of the transcriptional activity of PPARgamma in HUVEC cells.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29933613            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Studied vascular endothelial growth factor A (VEGFA) gene +936T\/C single nucleotide polymorphism; found it has no significant correlation with biliary atresia in the Southern Chinese Han population.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29251369            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            miR125 targeted and inhibited the expression of VEGF through target sites located in the 3' untranslated region of VEGF mRNA.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29693153            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            higher levels of IL-6 and VEGF-A were significantly associated with shorter progression free survival in epithelial ovarian cancer            \u003ca rel=\"nofollow\"\u003e             PMID:                        29572186            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            results suggest that PEDF act as a multipotent factor in the skin and the imbalance of PEDF and VEGF may be responsible for the transformation from normal skin to psoriasis.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29579411            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            RTPCR analysis revealed that the expression levels of COX2 and VEGF were downregulated following morusin treatment... morusin significantly inhibited the proliferation of the lung cancer cell line A549, and may have affected the invasion and migration of the cells by downregulating the expression of tumor angiogenesisrelated genes.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29749480            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            These results suggest that VM formation is increased by EBVLMP1 via VEGF\/VEGFR1 signaling and provide additional information to clarify the role of EBVLMP1 in nasopharyngeal carcinoma (NPC)pathophysiology            \u003ca rel=\"nofollow\"\u003e             PMID:                        29749553            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Data suggest that expression of mRNA for ghrelin and VEGFA are up-regulated in endometrium of women with recurrent miscarriage; thus, ghrelin and VEGFA may play roles in pathogenesis of recurrent miscarriage. These case-control studies were conducted with endometrial tissue obtained during secretory phase of menstrual cycle. (VEGFA = vascular endothelial growth factor A)            \u003ca rel=\"nofollow\"\u003e             PMID:                        29221937            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            AEG-1 was found to be significantly associated with hypoxia in ovarian cancer by regulating the HIF-1alpha\/NF-kappaB\/VEGF pathway.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29770329            \u003c\/a\u003e \u003c\/li\u003e \u003c\/div\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"20ug","offer_id":43999236653281,"sku":"BLC-07867P","price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/products\/CSB-YP025833HU-SDS.jpg?v=1690519321"},{"product_id":"recombinant-rat-vascular-endothelial-growth-factor-a-vegfa-protein-his-blc-09296p","title":"Recombinant Rat Vascular Endothelial Growth Factor A (VEGFA) Protein (His)","description":"\u003cmeta charset=\"utf-8\"\u003e\u003ch3\u003eProduct Overview\u003c\/h3\u003e\u003ctable width=\"100%\"\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRecombinant Rat Vascular Endothelial Growth Factor A (VEGFA) Protein (His) is produced by our E.coli expression system. This is a full length protein.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eGreater than 90% as determined by SDS-PAGE.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eUniprotkb\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003ca rel=\"nofollow\" target=\"_blank\"\u003e           P16612          \u003c\/a\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Symbol\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eVEGFA\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSynonyms\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eVegfa; Vegf; Vascular endothelial growth factor A; VEGF-A; Vascular permeability factor; VPF\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSpecies\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRattus norvegicus (Rat)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression System\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eE.coli\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTag\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eN-6His\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Protein Sequence\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eAPTTEGEQKAHEVVKFMDVYQRSYCRPIETLVDIFQEYPDEIEYIFKPSCVPLMRCAGCCNDEALECVPTSESNVTMQIMRIKPHQSQHIGEMSFLQHSRCECRPKKDRTKPEKKSVRGKGKGQKRKRKKSRFKSWSVHCEPCSERRKHLFVQDPQTCKCSCKNTDSRCKARQLELNERTCRCDKPRR\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression Range\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e27-214aa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eProtein Length\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eFull Length of Mature Protein\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eMol. Weight\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e26.1kDa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eResearch Area\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eOthers\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eForm\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLiquid or Lyophilized powder\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eBuffer\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLiquid form: default storage buffer is Tris\/PBS-based buffer, 5%-50% glycerol. Lyophilized powder form: the buffer before lyophilization is Tris\/PBS-based buffer, 6% Trehalose, pH 8.0.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eReconstitution\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eBriefly centrifuged the vial prior to opening to bring the contents to the bottom. Reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg\/mL. It is recommended to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C\/-80°C. The default final concentration of glycerol is 50%.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e1. Store at -20°C\/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C\/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C\/-80°C.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eNotes\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRepeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e \u003ch3\u003eTarget Details\u003c\/h3\u003e\u003ctable width=\"100%\"\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Function\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eGrowth factor active in angiogenesis, vasculogenesis and endothelial cell growth. Induces endothelial cell proliferation, promotes cell migration, inhibits apoptosis and induces permeabilization of blood vessels. Binds to the FLT1\/VEGFR1 and KDR\/VEGFR2 receptors, heparan sulfate and heparin. May play a role in increasing vascular permeability during lactation, when increased transport of molecules from the blood is required for efficient milk protein synthesis. Binding to NRP1 receptor initiates a signaling pathway needed for motor neuron axon guidance and cell body migration, including for the caudal migration of facial motor neurons from rhombomere 4 to rhombomere 6 during embryonic development.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSubcellular Location\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eSecreted.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eProtein Families\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003ePDGF\/VEGF growth factor family\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDatabase References\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003cdiv\u003e \u003cp\u003e           KEGG:           \u003ca rel=\"nofollow\"\u003e            rno:83785           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           STRING:           \u003ca rel=\"nofollow\"\u003e            10116.ENSRNOP00000026637           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           UniGene:           \u003ca rel=\"nofollow\"\u003e             PMID:                        29486133            \u003c\/a\u003e  \u003c\/p\u003e\n\u003cli\u003e            the epigenetic mechanisms involved in the physical exercise-mediated induction of VegfA expression, were examined.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27975171            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Our data suggest that activation of the GPR91-ERK1\/2-C\/EBP beta (c-Fos, HIF-1a) signaling pathway plays a tonic role in regulating VEGF transcription in rat retinal ganglion cells.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28374767            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            present results suggested that pathologically high cyclic stretch induces the shuttling of SRSF1 which results in the secretive pattern splicing of VEGFA and finally contributes to the proliferation of vascular smooth muscle cells.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29974845            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Results indicate that vascular endothelial growth factor (VEGF) is a vital important factor that contributes to the small-airway remodelling in a rat model of Chronic obstructive pulmonary disease through promoting angiogenesis, which mainly depend on the specific binding between VEGF and VEGF receptor 1 and can be effectively attenuated by sunitinib.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28117425            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            150-kDa oxygen-regulated protein (ORP150) levels were significantly increased in rat retinas after induction of diabetes. Vascular endothelial growth factor (VEGF) and the pro-inflammatory cytokines interleukin-6 (IL-6) and tumour necrosis factor-alpha (TNF-alpha) induced upregulation of ORP150 in HRMEC.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29098793            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Expression of vascular endothelial growth factor in cardiac repair: Signaling mechanisms mediating vascular protective effects            \u003ca rel=\"nofollow\"\u003e             PMID:                        29462681            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            VEGF-A expression in soft tissues repaired by shockwave therapy            \u003ca rel=\"nofollow\"\u003e             PMID:                        29921384            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            While the mRNA expression of the proangiogenic factors VEGF, transforming growth factor-beta1 (TGF-beta1), and adrenomedullin dropped at 0 h post-hypoxia compared to normoxic control, no changes were detected at the protein level, showing an impaired response of these proangiogenic factors to hypoxia in the aged striatum            \u003ca rel=\"nofollow\"\u003e             PMID:                        28501895            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Kisspeptin-10 prevents the increased vascular permeability of ovarian hyperstimulation syndrome by the activation of KISS1R and the inhibition of VEGF.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28676533            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The results indicate that VEGF promotes endothelial progenitor cell differentiation and vascular repair through Cx43.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29065929            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The results obtained in the study revealed that down-regulation of VEGF by RNAi could be a novel target approach for the treatment of failure (UFF) in rats with peritoneal dialysis.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28733472            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            VEGF165 induces differentiation of hair follicle stem cells into endothelial cells and plays a role in in vivo angiogenesis.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28244687            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Enhanced neuroprotective efficacy of bone marrow mesenchymal stem cells co-overexpressing BDNF and VEGF in a rat model of cardiac arrest-induced global cerebral ischemia            \u003ca rel=\"nofollow\"\u003e             PMID:                        28492549            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            this is the first report describing the use of novel polymeric gene carriers for the delivery of VEGF gene to DA neurons with improved transfection efficiency. Finally, the study will lead to a significant advancement in the field of non-viral Parkinson's Disease gene therapy treatment.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28025049            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            the results indicate that, Osx-overexpression promotes ADSCs' osteogenesis both in vitro and in vivo, which could be enhanced by release of VEGF.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28107808            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Following IL-1beta (50mug\/kg ip.) administration, a higher serum IL-1beta level was detected in females than in males. In male rats, IL-1beta decreased BDNF mRNA in all the brain structures, except for the pituitary, and VEGF mRNA in the amygdala.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27744091            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            VEGF knockdown can enhance chondrogenesis and prevent osteoarthritis progression.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27164955            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Here we report for the first time the expression of a rare and unusually potent splice variant, VEGF 111 , in vivo in mammals. Our discovery of VEGF 111 in the uterus of both a eutherian (rat) and a marsupial (fat-tailed dunnart) suggests that the splice variant may be common to all mammals            \u003ca rel=\"nofollow\"\u003e             PMID:                        27722773            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Data indicate vascular endothelial growth factor A (VEGFA) as a target gene of miR-200b.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28122882            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Our results suggest that hUCMSCs can promote ovarian expression of HGF, VEGF, and IGF-1 through secreting those cytokines, resulting in improving ovarian reserve function and withstanding ovarian senescence.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28279229            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            We demonstrate that a fine balance of VEGF and angiopoietin signaling is required for the formation of a functional vascular network.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27868196            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            results indicate that the paracrine factor, VEGF, derived from transplanted BM-MSCs, regulated the expression of miRNAs such as miRNA-23a and miRNA-92a and exerted anti-apoptotic effects in cardiomyocytes after MI            \u003ca rel=\"nofollow\"\u003e             PMID:                        28662151            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            VEGF expression increased markedly in the cerebellum and mildly in the occipital lobe following up to 4 weeks of exposure to 20-ppm methylmercury. VEGF expression was detected mainly in astrocytes of the blood brain barrier.  Intravenous administration of anti-VEGF neutralizing antibody mildly reduced the rate of hind-limb crossing signs observed in MeHg-exposed rats.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28118383            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Overexpressed long non-coding RNA (lncRNA) ANRIL upregulates vascular endothelial growth factor (VEGF) and promotes angiogenesis by activating NF-kappa B (NF-kappaB) signaling pathway in diabetes mellitus (DM) combined with cerebral infarction (DM + CI) rats.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28060742            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Vitexicarpine increased rats' survival time and decreased serum alpha-fetoprotein as well as it ameliorated fibrosis and massive hepatic tissue breakdown. It attenuated hepatocellular carcinoma-induced protein and gene expression of vascular endothelial growth factor            \u003ca rel=\"nofollow\"\u003e             PMID:                        28651490            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Knockdown of hepatic VEGF decreases hepatic sdf1 expression and plasma sdf1 levels.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26939868            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            XBP1 regulates VEGF-mediated cardiac angiogenesis.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27133203            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            a novel rodent model to reproduce much of the known phenotype of CTEPH, including the pivotal pathophysiological role of impaired vascular endothelial growth factor-dependent vascular remodeling, is reported.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28183533            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            VEGF treatment increases expression of HGF in vitro and in vivo and that, based on a series of integrative studies, we suggest that the effects of VEGF are mediated through downstream HGF signaling.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27036872            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            MiR-21 exerts protective effects on endothelial injury through the PTEN\/VEGF pathway after acute myocardial infarction.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27708252            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Chemerin and VEGF play important roles in diabetic nephropathy.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27612613            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Vegf expression is increased in brain from ischemic rats following treadmill exercise.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27747480            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            these results suggested that miRNA-29a suppresses cardiac fibrosis and fibroblasts proliferation via targeting VEGF-A\/MAPK signal pathway implicating that miRNA-29a might play a role in the treatment of cardiac fibrosis.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27060017            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Data suggest that a vascular endothelial growth factor (VEGF) signaling defect possibly plays an important role in defective embryonic airway branching.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27372649            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            the inhibitory effect of miR1405p on angiogenesis was attenuated by the overexpression of VEGFA.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27035554            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            we aimed to investigate the effect on angiogenesis of endoglin and VEGF expression in 1, 2-dimethylhydrazine dihydrochloride (DMH)-induced rat colon carcinogenesis and evaluated the implementation of COX2 inhibitors for molecular targets on tumor considering the above-mentioned mechanisms.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27466499            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            This study demonstrated that vegf increases in male rat with aneurysmal subarachnoid hemorrhage.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26923576            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            This study demonstrates that hyperthyroidism may have an effect on the development of rat adrenal glands mediated by VEGF expression, angiogenesis, and apoptosis.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26708182            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            This PHD-2-mediated transcriptional activation may be important for regulating VEGF expression through HIF-1a signaling in LCs during corpus luteum development in mammals.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26681021            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Results indicate that chronic stress enhances vulnerability of brain-derived neurotrophic factor and vascular endothelial growth factor response to neuroinflammation.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26396035            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Identify a mechanism of VEGF overexpression in liver and mesentery that promotes pathologic, but not physiologic, angiogenesis, via sequential and nonredundant functions of CPEB1 and CPEB4.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26627607            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The increased level of VEGF expression in the nicotine-treated group may have affected endothelial cell apoptosis            \u003ca rel=\"nofollow\"\u003e             PMID:                        27363062            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            TP53, BCL-2, and VEGFA genes may participate in the proliferation of esophagus cancer cells in a synergistic manner            \u003ca rel=\"nofollow\"\u003e             PMID:                        26439224            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            results indicate OVX may induce 3-D capillary regression in soleus muscle through an imbalance between VEGF-A and TSP-1 expression, possibly associated with decreased exercise tolerance in ovariectomized rats.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26092525            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            PHD2-mediated transcriptional activation may be one of the mechanisms regulating VEGF expression in luteal cells during mammalian corpus luteum development.            \u003ca rel=\"nofollow\"\u003e             PMID:                        25975603            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Cardiomyocyte VEGF activates EC Notch signaling, facilitating GPIHBP1-mediated translocation of LPL across EC and regulating LPL-derived fatty acid delivery to the cardiomyocytes.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26586663            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Expression in control and blank groups was similar at 3 and 6 months. Atorvastatin can inhibit VEGI and vascular endothelial growth factor expression to protect rats from diabetic retinopathy            \u003ca rel=\"nofollow\"\u003e             PMID:                        26125742            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            VEGF is implicated in the pathogenesis of inflammation after electrical burns.            \u003ca rel=\"nofollow\"\u003e             PMID:                        25466960            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            No significant differences were noted in the expression of VEGF in rat tympanic membrane perforation.            \u003ca rel=\"nofollow\"\u003e             PMID:                        25920966            \u003c\/a\u003e \u003c\/li\u003e \u003c\/div\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"20ug","offer_id":43999423004897,"sku":"BLC-09296P","price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/products\/CSB-RP082494r-SDS.jpg?v=1690523839"},{"product_id":"recombinant-fitc-labeled-human-vegf165-protein-active-blk-00210p","title":"Recombinant FITC-Labeled Human VEGF165 Protein, Active","description":"\u003cmeta charset=\"utf-8\"\u003e\n\u003ch3 class=\"font_9\"\u003e\n\u003cspan\u003eProduct Overview\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003ctable width=\"100%\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRecombinant FITC-Labeled Human VEGF165 Protein is expressed from HEK293 with His tag and Avi tag at the C-Terminus.It contains Ala27-Arg191.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u0026gt; 95% as determined by Tris-Bis PAGE;\u0026gt; 95% as determined by HPLC\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eAccession\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003ca rel=\"nofollow noopener noreferrer\" target=\"_blank\"\u003e P15692\u003c\/a\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Symbol\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eVEGF165\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSpecies\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eHuman\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression System\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eHEK293\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTag\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eC-His-Avi\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression Range\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eAla27-Arg191\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eMol. Weight\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eThe protein has a predicted MW of 22.2 kDa. Due to glycosylation, the protein migrates to 28-33 kDa under reduced (R) condition, 45-55 kDa under Non reducing (N) condition based on Tris-Bis PAGE result.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eForm\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eFormulation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized from 0.22 um filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eEndotoxin\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLess than 1EU per ug by the LAL method.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eActivity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eImmobilized FITC-Labeled Human VEGF165, His Tag at 0.2ug\/ml (100ul\/well) on the plate. Dose response curve for Anti-VEGF165 Antibody, hFc Tag with the EC50 of 22.3ng\/ml determined by ELISA. Contact us for detailed testing images.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eReconstituted protein stable at -80°C for 12 months, 4°C for 1 week. Use a manual defrost freezer and avoid repeated freeze-thaw cycles.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eShipping\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eShipped at ambient temperature.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eGene Background\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eVascular endothelial growth factor (VEGF or VEGF-A), also known as vascular permeability factor (VPF), is a potent mediator of both angiogenesis and vasculogenesis in the fetus and adult. VEGF165 appears to be the most abundant and potent isoform, followed by VEGF121 and VEGF189.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"100UG","offer_id":45123157295329,"sku":"BLK-00210P-100UG","price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/files\/20230918164428.png?v=1715128562"},{"product_id":"recombinant-human-vegf121-protein-active-blk-00535p","title":"Recombinant Human VEGF121 Protein, Active","description":"\u003cmeta charset=\"utf-8\"\u003e\n\u003ch3 class=\"font_9\"\u003e\n\u003cspan\u003eProduct Overview\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003ctable width=\"100%\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRecombinant Human VEGF121 Protein is expressed from HEK293 without tag.It contains Ala27-Arg147.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u0026gt; 95% as determined by Tris-Bis PAGE;\u0026gt; 90% as determined by HPLC\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eAccession\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003ca rel=\"nofollow noopener noreferrer\" target=\"_blank\"\u003e P15692\u003c\/a\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Symbol\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eVEGF121\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSpecies\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eHuman\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression System\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eHEK293\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTag\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eNo Tag\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression Range\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eAla27-Arg147\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eMol. Weight\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eThe protein has a predicted MW of 14.07 kDa. Due to glycosylation, the protein migrates to 15-25 kDa based on Tris-Bis PAGE result.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eForm\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eFormulation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized from 0.22um filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eEndotoxin\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLess than 1EU per ug by the LAL method.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eActivity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eImmobilized Human VEGF121, No Tag at 0.5ug\/ml (100ul\/well) on the plate. Dose response curve for Human VEGF R1, His Tag with the EC50 of 21.7ng\/ml determined by ELISA. Contact us for detailed testing images.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eReconstituted protein stable at -80°C for 12 months, 4°C for 1 week. Use a manual defrost freezer and avoid repeated freeze-thaw cycles.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eShipping\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eShipped at ambient temperature.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eGene Background\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eVascular endothelial growth factor (VEGF or VEGF-A), also known as vascular permeability factor (VPF), is a potent mediator of both angiogenesis and vasculogenesis in the fetus and adult. VEGF165 appears to be the most abundant and potent isoform, followed by VEGF121 and VEGF189.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"100UG","offer_id":45123176890593,"sku":"BLK-00535P-100UG","price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/files\/20221128183128.png?v=1715129542"},{"product_id":"biotinylated-human-vegf165-protein-active-blk-01212p","title":"Biotinylated Human VEGF165 Protein, Active","description":"\u003cmeta charset=\"utf-8\"\u003e\n\u003ch3 class=\"font_9\"\u003e\n\u003cspan\u003eProduct Overview\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003ctable width=\"100%\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRecombinant Biotinylated Human VEGF165 Protein is expressed from HEK293 with His tag and Avi tag at the C-Terminus.It contains Ala27-Arg191.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u0026gt; 95% as determined by Tris-Bis PAGE\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eAccession\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003ca rel=\"nofollow noopener noreferrer\" target=\"_blank\"\u003e P15692\u003c\/a\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Symbol\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eVEGF165\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSynonyms\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eVEGF; VEGFA; MVCD1; VAS; VEGFMGC70609; VPF; RP1-261G23.1; MGC70609\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSpecies\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eHuman\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression System\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eHEK293\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTag\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eC-His-Avi\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression Range\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eAla27-Arg191\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eMol. Weight\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eThe protein has a predicted MW of 22.2 kDa. Due to glycosylation, the protein migrates to 28-35 kDa under reduced (R) condition, 45-60 kDa under Non reducing (N) condition based on Tris-Bis PAGE result.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eForm\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eFormulation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized from 0.22um filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eEndotoxin\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLess than 1EU per ug by the LAL method.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eActivity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eImmobilized Anti-VEGF165 Antibody at 1ug\/ml (100ul\/well) on the plate. Dose response curve for Biotinylated Human VEGF165, His Tag with the EC50 of 13.7ng\/ml determined by ELISA. Contact us for detailed testing images.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eReconstituted protein stable at -80°C for 12 months, 4°C for 1 week. Use a manual defrost freezer and avoid repeated freeze-thaw cycles.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eShipping\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eShipped at ambient temperature.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eGene Background\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eVascular endothelial growth factor (VEGF or VEGF-A), also known as vascular permeability factor (VPF), is a potent mediator of both angiogenesis and vasculogenesis in the fetus and adult. VEGF165 appears to be the most abundant and potent isoform, followed by VEGF121 and VEGF189.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"100UG","offer_id":45123245703393,"sku":"BLK-01212P-100UG","price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/files\/20230320145549.png?v=1715131743"},{"product_id":"recombinant-human-vegf165-protein-active-blk-01213p","title":"Recombinant Human VEGF165 Protein, Active","description":"\u003cmeta charset=\"utf-8\"\u003e\n\u003ch3 class=\"font_9\"\u003e\n\u003cspan\u003eProduct Overview\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003ctable width=\"100%\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRecombinant Human VEGF165 Protein is expressed from HEK293 with His tag and Avi tag at the C-Terminus.It contains Ala27-Arg191.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u0026gt; 95% as determined by Tris-Bis PAGE\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eAccession\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003ca rel=\"nofollow noopener noreferrer\" target=\"_blank\"\u003e P15692\u003c\/a\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Symbol\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eVEGF165\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSynonyms\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eVEGF; VEGFA; MVCD1; VAS; VEGFMGC70609; VPF; RP1-261G23.1; MGC70609\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSpecies\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eHuman\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression System\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eHEK293\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTag\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eC-His-Avi\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression Range\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eAla27-Arg191\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eMol. Weight\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eThe protein has a predicted MW of 22.2 kDa. Due to glycosylation, the protein migrates to 28-35 kDa under reduced (R) condition, 45-60 kDa under Non reducing (N) condition based on Tris-Bis PAGE result.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eForm\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eFormulation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized from 0.22um filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eEndotoxin\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLess than 1EU per ug by the LAL method.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eActivity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eImmobilized Human VEGF165 at 0.5ug\/ml (100ul\/well) on the plate. Dose response curve for Anti-VEGF165 Antibody, hFc Tag with the EC50 of 4.1ng\/ml determined by ELISA. Contact us for detailed testing images.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eReconstituted protein stable at -80°C for 12 months, 4°C for 1 week. Use a manual defrost freezer and avoid repeated freeze-thaw cycles.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eShipping\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eShipped at ambient temperature.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eGene Background\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eVascular endothelial growth factor (VEGF or VEGF-A), also known as vascular permeability factor (VPF), is a potent mediator of both angiogenesis and vasculogenesis in the fetus and adult. VEGF165 appears to be the most abundant and potent isoform, followed by VEGF121 and VEGF189.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"100UG","offer_id":45123245736161,"sku":"BLK-01213P-100UG","price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/files\/20230320145217.png?v=1715131745"},{"product_id":"biotinylated-human-vegf121-protein-active-blk-01214p","title":"Biotinylated Human VEGF121 Protein, Active","description":"\u003cmeta charset=\"utf-8\"\u003e\n\u003ch3 class=\"font_9\"\u003e\n\u003cspan\u003eProduct Overview\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003ctable width=\"100%\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRecombinant Biotinylated Human VEGF121 Protein is expressed from HEK293 with His tag and Avi tag at the C-Terminus.It contains Ala27-Arg147.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u0026gt; 95% as determined by Tris-Bis PAGE;\u0026gt; 95% as determined by HPLC\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eAccession\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003ca rel=\"nofollow noopener noreferrer\" target=\"_blank\"\u003e P15692\u003c\/a\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Symbol\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eVEGF121\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSynonyms\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eVEGF; VEGFA; MVCD1; VAS; VEGFMGC70609; VPF; RP1-261G23.1; MGC70609\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSpecies\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eHuman\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression System\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eHEK293\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTag\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eC-His-Avi\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression Range\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eAla27-Arg147\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eMol. Weight\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eThe protein has a predicted MW of 17 kDa. Due to glycosylation, the protein migrates to 18 kDa and 22-25 kDa under reduced (R) condition, 30 kDa and 32-40 kDa under Non reducing (N) condition based on Tris-Bis PAGE result.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eForm\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eFormulation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized from 0.22um filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eEndotoxin\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLess than 1EU per ug by the LAL method.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eActivity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eImmobilized Human VEGF R1, His Tag at 2ug\/ml (100ul\/well) on the plate. Dose response curve for Biotinylated Human VEGF121, His Tag with the EC50 of 36.5ng\/ml determined by ELISA. Contact us for detailed testing images.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eReconstituted protein stable at -80°C for 12 months, 4°C for 1 week. Use a manual defrost freezer and avoid repeated freeze-thaw cycles.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eShipping\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eShipped at ambient temperature.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eGene Background\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eVascular endothelial growth factor (VEGF or VEGF-A), also known as vascular permeability factor (VPF), is a potent mediator of both angiogenesis and vasculogenesis in the fetus and adult. VEGF165 appears to be the most abundant and potent isoform, followed by VEGF121 and VEGF189.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"100UG","offer_id":45123245867233,"sku":"BLK-01214P-100UG","price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/files\/20230320151807.png?v=1715131748"},{"product_id":"recombinant-human-vegf121-protein-active-blk-01215p","title":"Recombinant Human VEGF121 Protein, Active","description":"\u003cmeta charset=\"utf-8\"\u003e\n\u003ch3 class=\"font_9\"\u003e\n\u003cspan\u003eProduct Overview\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003ctable width=\"100%\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRecombinant Human VEGF121 Protein is expressed from HEK293 with His tag and Avi tag at the C-Terminus.It contains Ala27-Arg147.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u0026gt; 95% as determined by Tris-Bis PAGE\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eAccession\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003ca rel=\"nofollow noopener noreferrer\" target=\"_blank\"\u003e P15692\u003c\/a\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Symbol\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eVEGF121\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSynonyms\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eVEGF; VEGFA; MVCD1; VAS; VEGFMGC70609; VPF; RP1-261G23.1; MGC70609\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSpecies\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eHuman\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression System\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eHEK293\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTag\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eC-His-Avi\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression Range\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eAla27-Arg147\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eMol. Weight\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eThe protein has a predicted MW of 17 kDa. Due to glycosylation, the protein migrates to 18 kDa and 22-25 kDa under reduced (R) condition, 30 kDa and 32-40 kDa under Non reducing (N) condition based on Tris-Bis PAGE result.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eForm\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eFormulation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized from 0.22um filtered solution in PBS,250mM Arginine (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eEndotoxin\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLess than 1EU per ug by the LAL method.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eActivity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eImmobilized Human VEGF121, His Tag at 2ug\/ml (100ul\/Well). Dose response curve for Biotinylated Human VEGFR1, His Tag with the EC50 of 42ng\/ml determined by ELISA. Contact us for detailed testing images.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eReconstituted protein stable at -80°C for 12 months, 4°C for 1 week. Use a manual defrost freezer and avoid repeated freeze-thaw cycles.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eShipping\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eShipped at ambient temperature.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eGene Background\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eVascular endothelial growth factor (VEGF or VEGF-A), also known as vascular permeability factor (VPF), is a potent mediator of both angiogenesis and vasculogenesis in the fetus and adult. VEGF165 appears to be the most abundant and potent isoform, followed by VEGF121 and VEGF189.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"100UG","offer_id":45123245965537,"sku":"BLK-01215P-100UG","price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/files\/20230320144713.png?v=1715131751"},{"product_id":"recombinant-human-vegf165-protein-active-blk-01216p","title":"Recombinant Human VEGF165 Protein, Active","description":"\u003cmeta charset=\"utf-8\"\u003e\n\u003ch3 class=\"font_9\"\u003e\n\u003cspan\u003eProduct Overview\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003ctable width=\"100%\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRecombinant Human VEGF165 Protein is expressed from HEK293 without tag.It contains Ala27-Arg191.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u0026gt; 95% as determined by Tris-Bis PAGE;\u0026gt; 95% as determined by HPLC\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eAccession\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003ca rel=\"nofollow noopener noreferrer\" target=\"_blank\"\u003e P15692\u003c\/a\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Symbol\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eVEGF165\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSynonyms\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eVEGF; VEGFA; MVCD1; VAS; VEGFMGC70609; VPF; RP1-261G23.1; MGC70609\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSpecies\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eHuman\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression System\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eHEK293\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTag\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eNo Tag\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression Range\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eAla27-Arg191\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eMol. Weight\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eThe protein has a predicted MW of 19.2 kDa. Due to glycosylation, the protein migrates to 20-30 kDa based on Tris-Bis PAGE result.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eForm\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eFormulation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized from 0.22um filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eEndotoxin\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLess than 1EU per ug by the LAL method.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eActivity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eImmobilized Human VEGF165 at 1ug\/ml (100ul\/well) on the plate. Dose response curve for Human VEGFR2, mFc Tag with the EC50 of 42.3ng\/ml determined by ELISA. Contact us for detailed testing images.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eReconstituted protein stable at -80°C for 12 months, 4°C for 1 week. Use a manual defrost freezer and avoid repeated freeze-thaw cycles.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eShipping\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eShipped at ambient temperature.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eGene Background\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eHuman papillomavirus (HPV) infection is an established risk factor for cervical carcinogenesis. VEGF165 was significantly higher, whereas VEGFC and VEGFD were significantly lower in malignant cervical carcinoma tissues as compared to normal cervix tissues. Expression levels of VEGF121 and VEGFC were significantly associated with type of tumor growth while VEGF165 was significantly associated with lymph node metastasis.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"100UG","offer_id":45123246325985,"sku":"BLK-01216P-100UG","price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/files\/1607678693656020.jpg?v=1715131754"},{"product_id":"human-vegfa-polyclonal-antibody-blc-03596a","title":"Rabbit anti-Human VEGFA Polyclonal Antibody","description":"\u003cmeta charset=\"utf-8\"\u003e\n\u003ch3 class=\"font_9\"\u003e\n\u003cmeta charset=\"utf-8\"\u003e\n\u003cspan\u003eProduct Overview\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003ctable width=\"100%\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eProduct Title\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eRabbit anti-Human VEGFA Polyclonal Antibody\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eThe antibody against VEGFA was raised in rabbit using the Synthetic peptide of Human VEGFA as the immunogen. This antibody exists as a non-conjugated isotype IgG, Antigen affinity purified. This antibody has been validated on ELISA, WB, IHC.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eUniprot Id - Alink\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003e \u003ca rel=\"nofollow noopener noreferrer\" target=\"_blank\"\u003eP15692\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eHost Species\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eRabbit\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eReactivity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eHuman\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Name\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eVEGFA\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Synonyms\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eglioma-derived endothelial cell mitogen antibody; MGC70609 antibody; MVCD1 antibody; Vascular endothelial growth factor A antibody; Vascular Endothelial Growth Factor antibody; Vascular permeability factor antibody; VEGF antibody; VEGF-A antibody; VEGF165 antibody; Vegfa antibody; VEGFA_HUMAN antibody; VPF antibody\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eImmunogen Description\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eSynthetic peptide of Human VEGFA\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eImmunogen Species\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eHuman\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eImmunogen Sequence\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eComplete sequences for the immunogen, target protein, and peptides are available upon request.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eConjugate\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eNon-conjugated\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eClonality\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003ePolyclonal\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eIsotype\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eIgG\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003ePurification Method\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eAntigen affinity purified\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eBuffer\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003epH7.4 PBS, 0.05% NaN3, 40% Glycerol\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eForm\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eLiquid\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eApplication\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eELISA, WB, IHC\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage Conditions\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eUpon receipt, store at -20°C or -80°C. Avoid repeated freeze.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"Default Title","offer_id":46138305282273,"sku":"BLC-03596A","price":299.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/files\/CSB-PA379558-P.jpg?v=1738836021"},{"product_id":"recombinant-mouse-vegfa-protein-blt-03281p","title":"Mouse Vegfa (Vascular Endothelial Growth Factor A, Long Form) - Recombinant Protein","description":"\u003cmeta charset=\"utf-8\"\u003e\n\u003ch3 class=\"font_9\"\u003e\n\u003cmeta charset=\"utf-8\"\u003e\n\u003cspan\u003eProduct Overview\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003ctable width=\"100%\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eProduct Name\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eRecombinant Mouse Vascular Endothelial Growth Factor A (VEGFA) Protein\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eProduct Overview\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eThis recombinant mouse Vascular Endothelial Growth Factor A (VEGFA) protein includes amino acids 27-146aa of the target gene is expressed in E.coli.The protein is supplied in lyophilized form and formulated in phosphate buffered saline (pH7.4) containing 0.01% sarcosyl, 5% trehaloseprior to lyophilization.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Uniprot Id\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eQ00731\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eRecommended Name\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eVascular endothelial growth factor A, long form\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eGene Name\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eVegfa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eSynonyms\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eVegf-a, Vegf120, Vegf164, Vegf188, Vpf, Vascular endothelial growth factor A isoform 3\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eSpecies\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eMouse\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003ePredicted Molecular Mass\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003e18 kDa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression System\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eE.coli\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression Range\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003e27-146aa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eTag\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eN-6His\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003e\u0026gt;95%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eFormulation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eLyophilized\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eBuffer\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003ePhosphate buffered saline (pH7.4) containing 0.01% sarcosyl, 5%Trehalose\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage Condition\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003e1. Store at -20°C\/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C\/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C\/-80°C.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eReconstitution Instruction\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eBriefly centrifuged the vial prior to opening to bring the contents to the bottom. Reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg\/mL. It is recommended to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C\/-80°C. The default final concentration of glycerol is 50%.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eApplications\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003ePositive Control; Immunogen; SDS-PAGE; WB\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"100ug","offer_id":46701103939809,"sku":"BLT-03281P","price":556.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/files\/1gs1icuke1n5116f4j.jpg?v=1753342179"},{"product_id":"recombinant-human-vegfa-protein-blt-03283p","title":"Human VEGFA (Vascular Endothelial Growth Factor A, Long Form) - Recombinant Protein","description":"\u003cmeta charset=\"utf-8\"\u003e\n\u003ch3 class=\"font_9\"\u003e\n\u003cmeta charset=\"utf-8\"\u003e\n\u003cspan\u003eProduct Overview\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003ctable width=\"100%\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eProduct Name\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eRecombinant Human Vascular Endothelial Growth Factor 121 (VEGF121\/VEGFA) Protein\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eProduct Overview\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eThis recombinant human Vascular Endothelial Growth Factor 121 (VEGF121\/VEGFA) protein includes amino acids 28-147aa of the target gene is expressed in E.coli.The protein is supplied in lyophilized form and formulated in phosphate buffered saline (pH7.4) containing 0.01% sarcosyl, 5% trehaloseprior to lyophilization.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Uniprot Id\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eP15692\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eRecommended Name\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eVascular endothelial growth factor A, long form\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eGene Name\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eVEGFA\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eSynonyms\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eVascular endothelial growth factor A isoform f , VPF, VEGF, VEGF-A, Vascular endothelial growth fact\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eSpecies\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eHuman\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003ePredicted Molecular Mass\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003e15 kDa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression System\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eE.coli\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression Range\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003e28-147aa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eTag\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eN-6His\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003e\u0026gt;95%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eFormulation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eLyophilized\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eBuffer\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003ePhosphate buffered saline (pH7.4) containing 0.01% sarcosyl, 5%Trehalose\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage Condition\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003e1. Store at -20°C\/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C\/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C\/-80°C.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eReconstitution Instruction\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eBriefly centrifuged the vial prior to opening to bring the contents to the bottom. Reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg\/mL. It is recommended to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C\/-80°C. The default final concentration of glycerol is 50%.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eApplications\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003ePositive Control; Immunogen; SDS-PAGE; WB\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eResearch Area\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eCancer\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Function\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eGrowth factor active in angiogenesis, vasculogenesis and endothelial cell growth. Induces endothelial cell proliferation, promotes cell migration, inhibits apoptosis and induces permeabilization of blood vessels. Binds to the FLT1\/VEGFR1 and KDR\/VEGFR2 receptors, heparan sulfate and heparin. NRP1\/Neuropilin-1 binds isoforms VEGF-165 and VEGF-145. Isoform VEGF165B binds to KDR but does not activate downstream signaling pathways, does not activate angiogenesis and inhibits tumor growth. Binding to NRP1 receptor initiates a signaling pathway needed for motor neuron axon guidance and cell body migration, including for the caudal migration of facial motor neurons from rhombomere 4 to rhombomere 6 during embryonic development.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eSubcellular Location\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eSecreted. Note=VEGF121 is acidic and freely secreted. VEGF165 is more basic, has heparin-binding properties and, although a significant proportion remains cell-associated, most is freely secreted. VEGF189 is very basic, it is cell-associated after secretion and is bound avidly by heparin and the extracellular matrix, although it may be released as a soluble form by heparin, heparinase or plasmin.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eProtein Family\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003ePDGF\/VEGF growth factor family\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eAssociated Diseases\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eMicrovascular complications of diabetes 1 (MVCD1)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eTissue Specificity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eIsoform VEGF189, isoform VEGF165 and isoform VEGF121 are widely expressed. Isoform VEGF206 and isoform VEGF145 are not widely expressed. A higher level expression seen in pituitary tumors as compared to the pituitary gland.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"100ug","offer_id":46701104529633,"sku":"BLT-03283P","price":556.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/files\/1gs1idgi014t13u1j.jpg?v=1753342189"},{"product_id":"recombinant-human-vegf121-vegfa-protein-blt-03284p","title":"Human VEGFA (Vascular Endothelial Growth Factor A, Long Form) - Recombinant Protein","description":"\u003cmeta charset=\"utf-8\"\u003e\n\u003ch3 class=\"font_9\"\u003e\n\u003cmeta charset=\"utf-8\"\u003e\n\u003cspan\u003eProduct Overview\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003ctable width=\"100%\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eProduct Name\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eRecombinant Human VEGF121 (VEGFA) Protein\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eProduct Overview\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eThis recombinant human VEGF121 (VEGFA) protein includes amino acids 207-327aa of the target gene is expressed in E.coli.The protein is supplied in lyophilized form and formulated in phosphate buffered saline (pH7.4) containing 0.01% sarcosyl, 5% trehaloseprior to lyophilization.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Uniprot Id\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eP15692\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eRecommended Name\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eVascular endothelial growth factor A, long form\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eGene Name\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eVEGFA\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eSynonyms\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eVPF, VEGF, VEGF-A, MGC70609, VEGF121, Vascular endothelial growth factor A isoform f, Vascular endot\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eSpecies\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eHuman\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003ePredicted Molecular Mass\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003e16.3 kDa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression System\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eE.coli\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression Range\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003e207-327aa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eTag\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eN-6His\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003e\u0026gt;85%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eFormulation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eLyophilized\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eBuffer\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003ePhosphate buffered saline (pH7.4) containing 0.01% sarcosyl, 5%Trehalose\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage Condition\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003e1. Store at -20°C\/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C\/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C\/-80°C.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eReconstitution Instruction\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eBriefly centrifuged the vial prior to opening to bring the contents to the bottom. Reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg\/mL. It is recommended to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C\/-80°C. The default final concentration of glycerol is 50%.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eApplications\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003ePositive Control; Immunogen; SDS-PAGE; WB\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eResearch Area\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eCancer\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Function\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eGrowth factor active in angiogenesis, vasculogenesis and endothelial cell growth. Induces endothelial cell proliferation, promotes cell migration, inhibits apoptosis and induces permeabilization of blood vessels. Binds to the FLT1\/VEGFR1 and KDR\/VEGFR2 receptors, heparan sulfate and heparin. NRP1\/Neuropilin-1 binds isoforms VEGF-165 and VEGF-145. Isoform VEGF165B binds to KDR but does not activate downstream signaling pathways, does not activate angiogenesis and inhibits tumor growth. Binding to NRP1 receptor initiates a signaling pathway needed for motor neuron axon guidance and cell body migration, including for the caudal migration of facial motor neurons from rhombomere 4 to rhombomere 6 during embryonic development.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eSubcellular Location\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eSecreted. Note=VEGF121 is acidic and freely secreted. VEGF165 is more basic, has heparin-binding properties and, although a significant proportion remains cell-associated, most is freely secreted. VEGF189 is very basic, it is cell-associated after secretion and is bound avidly by heparin and the extracellular matrix, although it may be released as a soluble form by heparin, heparinase or plasmin.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eProtein Family\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003ePDGF\/VEGF growth factor family\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eAssociated Diseases\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eMicrovascular complications of diabetes 1 (MVCD1)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eTissue Specificity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eIsoform VEGF189, isoform VEGF165 and isoform VEGF121 are widely expressed. Isoform VEGF206 and isoform VEGF145 are not widely expressed. A higher level expression seen in pituitary tumors as compared to the pituitary gland.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"100ug","offer_id":46701104693473,"sku":"BLT-03284P","price":556.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/files\/1gs1idp2v14g614a5j.jpg?v=1753342194"},{"product_id":"recombinant-human-vegfa-protein-blt-03285p","title":"Human VEGFA (Vascular Endothelial Growth Factor A, Long Form) - Recombinant Protein","description":"\u003cmeta charset=\"utf-8\"\u003e\n\u003ch3 class=\"font_9\"\u003e\n\u003cmeta charset=\"utf-8\"\u003e\n\u003cspan\u003eProduct Overview\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003ctable width=\"100%\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eProduct Name\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eRecombinant Human Eukaryotic Vascular Endothelial Growth Factor 165 (VEGF165\/VEGFA) Protein\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eProduct Overview\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eThis recombinant human Eukaryotic Vascular Endothelial Growth Factor 165 (VEGF165\/VEGFA) protein includes amino acids 1-191aa of the target gene is expressed in 293F cell.The protein is supplied in lyophilized form and formulated in phosphate buffered saline (pH7.4) containing 0.01% sarcosyl, 5% trehaloseprior to lyophilization.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Uniprot Id\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eP15692\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eRecommended Name\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eVascular endothelial growth factor A, long form\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eGene Name\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eVEGFA\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eSynonyms\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eVascular endothelial growth factor A, MVCD1, VEGF, VPF\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eSpecies\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eHuman\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003ePredicted Molecular Mass\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003e20\/22 kDa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression System\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eMammalian Cell\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression Range\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003e1-191aa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eTag\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eN-6His\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003e\u0026gt;95%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eFormulation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eLyophilized\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eBuffer\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003ePhosphate buffered saline (pH7.4) containing 0.01% sarcosyl, 5%Trehalose\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage Condition\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003e1. Store at -20°C\/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C\/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C\/-80°C.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eReconstitution Instruction\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eBriefly centrifuged the vial prior to opening to bring the contents to the bottom. Reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg\/mL. It is recommended to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C\/-80°C. The default final concentration of glycerol is 50%.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eApplications\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003ePositive Control; Immunogen; SDS-PAGE; WB\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eResearch Area\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eCancer\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Function\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eGrowth factor active in angiogenesis, vasculogenesis and endothelial cell growth. Induces endothelial cell proliferation, promotes cell migration, inhibits apoptosis and induces permeabilization of blood vessels. Binds to the FLT1\/VEGFR1 and KDR\/VEGFR2 receptors, heparan sulfate and heparin. NRP1\/Neuropilin-1 binds isoforms VEGF-165 and VEGF-145. Isoform VEGF165B binds to KDR but does not activate downstream signaling pathways, does not activate angiogenesis and inhibits tumor growth. Binding to NRP1 receptor initiates a signaling pathway needed for motor neuron axon guidance and cell body migration, including for the caudal migration of facial motor neurons from rhombomere 4 to rhombomere 6 during embryonic development.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eSubcellular Location\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eSecreted. Note=VEGF121 is acidic and freely secreted. VEGF165 is more basic, has heparin-binding properties and, although a significant proportion remains cell-associated, most is freely secreted. VEGF189 is very basic, it is cell-associated after secretion and is bound avidly by heparin and the extracellular matrix, although it may be released as a soluble form by heparin, heparinase or plasmin.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eProtein Family\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003ePDGF\/VEGF growth factor family\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eAssociated Diseases\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eMicrovascular complications of diabetes 1 (MVCD1)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eTissue Specificity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eIsoform VEGF189, isoform VEGF165 and isoform VEGF121 are widely expressed. Isoform VEGF206 and isoform VEGF145 are not widely expressed. A higher level expression seen in pituitary tumors as compared to the pituitary gland.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"100ug","offer_id":46701104824545,"sku":"BLT-03285P","price":556.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/files\/1h7pmt8hk1krb1obkj.jpg?v=1753342198"},{"product_id":"recombinant-human-vegf165-vegfa-protein-blt-03286p","title":"Human VEGFA (Vascular Endothelial Growth Factor A, Long Form) - Recombinant Protein","description":"\u003cmeta charset=\"utf-8\"\u003e\n\u003ch3 class=\"font_9\"\u003e\n\u003cmeta charset=\"utf-8\"\u003e\n\u003cspan\u003eProduct Overview\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003ctable width=\"100%\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eProduct Name\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eRecombinant Human VEGF165 (VEGFA) Protein\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eProduct Overview\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eThis recombinant human VEGF165 (VEGFA) protein includes amino acids 207-370aa of the target gene is expressed in E.coli.The protein is supplied in lyophilized form and formulated in phosphate buffered saline (pH7.4) containing 0.01% sarcosyl, 5% trehaloseprior to lyophilization.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Uniprot Id\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eP15692\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eRecommended Name\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eVascular endothelial growth factor A, long form\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eGene Name\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eVEGFA\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eSynonyms\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eVascular endothelial growth factor A, VEGF, MVCD1, VPF\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eSpecies\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eHuman\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003ePredicted Molecular Mass\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003e19.3 kDa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression System\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eE.coli\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression Range\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003e207-370aa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003e\u0026gt;90%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eFormulation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eLyophilized\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eBuffer\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003ePhosphate buffered saline (pH7.4) containing 0.01% sarcosyl, 5%Trehalose\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage Condition\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003e1. Store at -20°C\/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C\/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C\/-80°C.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eReconstitution Instruction\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eBriefly centrifuged the vial prior to opening to bring the contents to the bottom. Reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg\/mL. It is recommended to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C\/-80°C. The default final concentration of glycerol is 50%.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eApplications\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003ePositive Control; Immunogen; SDS-PAGE; WB\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eResearch Area\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eCancer\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Function\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eGrowth factor active in angiogenesis, vasculogenesis and endothelial cell growth. Induces endothelial cell proliferation, promotes cell migration, inhibits apoptosis and induces permeabilization of blood vessels. Binds to the FLT1\/VEGFR1 and KDR\/VEGFR2 receptors, heparan sulfate and heparin. NRP1\/Neuropilin-1 binds isoforms VEGF-165 and VEGF-145. Isoform VEGF165B binds to KDR but does not activate downstream signaling pathways, does not activate angiogenesis and inhibits tumor growth. Binding to NRP1 receptor initiates a signaling pathway needed for motor neuron axon guidance and cell body migration, including for the caudal migration of facial motor neurons from rhombomere 4 to rhombomere 6 during embryonic development.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eSubcellular Location\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eSecreted. Note=VEGF121 is acidic and freely secreted. VEGF165 is more basic, has heparin-binding properties and, although a significant proportion remains cell-associated, most is freely secreted. VEGF189 is very basic, it is cell-associated after secretion and is bound avidly by heparin and the extracellular matrix, although it may be released as a soluble form by heparin, heparinase or plasmin.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eProtein Family\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003ePDGF\/VEGF growth factor family\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eAssociated Diseases\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eMicrovascular complications of diabetes 1 (MVCD1)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eTissue Specificity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eIsoform VEGF189, isoform VEGF165 and isoform VEGF121 are widely expressed. Isoform VEGF206 and isoform VEGF145 are not widely expressed. A higher level expression seen in pituitary tumors as compared to the pituitary gland.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"100ug","offer_id":46701104955617,"sku":"BLT-03286P","price":556.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/files\/1gs1iek4qd481b82j.jpg?v=1753342202"},{"product_id":"recombinant-human-vegf165-vegfa-protein-blt-03287p","title":"Human VEGFA (Vascular Endothelial Growth Factor A, Long Form) - Recombinant Protein","description":"\u003cmeta charset=\"utf-8\"\u003e\n\u003ch3 class=\"font_9\"\u003e\n\u003cmeta charset=\"utf-8\"\u003e\n\u003cspan\u003eProduct Overview\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003ctable width=\"100%\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eProduct Name\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eRecombinant Human VEGF165 (VEGFA) Protein\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eProduct Overview\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eThis recombinant human VEGF165 (VEGFA) protein includes amino acids 207-371aa of the target gene is expressed in E.coli.The protein is supplied in lyophilized form and formulated in phosphate buffered saline (pH7.4) containing 0.01% sarcosyl, 5% trehaloseprior to lyophilization.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Uniprot Id\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eP15692\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eRecommended Name\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eVascular endothelial growth factor A, long form\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eGene Name\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eVEGFA\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eSynonyms\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eVascular endothelial growth factor A isoform d, VPF, VEGF, VEGF-A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eSpecies\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eHuman\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003ePredicted Molecular Mass\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003e21.3 kDa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression System\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eE.coli\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression Range\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003e207-371aa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eTag\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eN-6His\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003e\u0026gt;85%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eFormulation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eLyophilized\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eBuffer\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003ePhosphate buffered saline (pH7.4) containing 0.01% sarcosyl, 5%Trehalose\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage Condition\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003e1. Store at -20°C\/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C\/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C\/-80°C.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eReconstitution Instruction\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eBriefly centrifuged the vial prior to opening to bring the contents to the bottom. Reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg\/mL. It is recommended to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C\/-80°C. The default final concentration of glycerol is 50%.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eApplications\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003ePositive Control; Immunogen; SDS-PAGE; WB\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eResearch Area\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eCancer\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Function\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eGrowth factor active in angiogenesis, vasculogenesis and endothelial cell growth. Induces endothelial cell proliferation, promotes cell migration, inhibits apoptosis and induces permeabilization of blood vessels. Binds to the FLT1\/VEGFR1 and KDR\/VEGFR2 receptors, heparan sulfate and heparin. NRP1\/Neuropilin-1 binds isoforms VEGF-165 and VEGF-145. Isoform VEGF165B binds to KDR but does not activate downstream signaling pathways, does not activate angiogenesis and inhibits tumor growth. Binding to NRP1 receptor initiates a signaling pathway needed for motor neuron axon guidance and cell body migration, including for the caudal migration of facial motor neurons from rhombomere 4 to rhombomere 6 during embryonic development.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eSubcellular Location\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eSecreted. Note=VEGF121 is acidic and freely secreted. VEGF165 is more basic, has heparin-binding properties and, although a significant proportion remains cell-associated, most is freely secreted. VEGF189 is very basic, it is cell-associated after secretion and is bound avidly by heparin and the extracellular matrix, although it may be released as a soluble form by heparin, heparinase or plasmin.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eProtein Family\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003ePDGF\/VEGF growth factor family\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eAssociated Diseases\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eMicrovascular complications of diabetes 1 (MVCD1)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eTissue Specificity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eIsoform VEGF189, isoform VEGF165 and isoform VEGF121 are widely expressed. Isoform VEGF206 and isoform VEGF145 are not widely expressed. A higher level expression seen in pituitary tumors as compared to the pituitary gland.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"100ug","offer_id":46701105119457,"sku":"BLT-03287P","price":556.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/files\/1gs1ietsj1huhgs4j.jpg?v=1753342206"},{"product_id":"recombinant-human-vegf-a-vegf121-vegfa-protein-blt-03900p","title":"Human VEGFA (Vascular Endothelial Growth Factor A, Long Form) - Recombinant Protein","description":"\u003cmeta charset=\"utf-8\"\u003e\n\u003ch3 class=\"font_9\"\u003e\n\u003cmeta charset=\"utf-8\"\u003e\n\u003cspan\u003eProduct Overview\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003ctable width=\"100%\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eProduct Name\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eRecombinant Human VEGF-A\/VEGF121 (VEGFA) Protein\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eProduct Overview\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eThis recombinant human VEGF-A\/VEGF121 (VEGFA) protein includes amino acids 27-147aa of the target gene is expressed in E.coli.The protein is supplied in lyophilized form and formulated in phosphate buffered saline (pH7.4) containing 0.01% sarcosyl, 5% trehaloseprior to lyophilization.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Uniprot Id\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eP15692\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eRecommended Name\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eVascular endothelial growth factor A, long form\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eGene Name\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eVEGFA\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eSynonyms\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eVascular endothelial growth factor A;VEGFA;VEGF-A;Vascular permeability factor;VPF;VEGF;VEGF121\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eSpecies\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eHuman\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003ePredicted Molecular Mass\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003e14.2 kDa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression System\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eE.coli\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression Range\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003e27-147aa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003e\u0026gt;95%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eFormulation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eLyophilized\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eBuffer\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003ePhosphate buffered saline (pH7.4) containing 0.01% sarcosyl, 5%Trehalose\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage Condition\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003e1. Store at -20°C\/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C\/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C\/-80°C.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eReconstitution Instruction\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eBriefly centrifuged the vial prior to opening to bring the contents to the bottom. Reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg\/mL. It is recommended to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C\/-80°C. The default final concentration of glycerol is 50%.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eApplications\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003ePositive Control; Immunogen; SDS-PAGE; WB\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eResearch Area\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eCancer\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Function\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eGrowth factor active in angiogenesis, vasculogenesis and endothelial cell growth. Induces endothelial cell proliferation, promotes cell migration, inhibits apoptosis and induces permeabilization of blood vessels. Binds to the FLT1\/VEGFR1 and KDR\/VEGFR2 receptors, heparan sulfate and heparin. NRP1\/Neuropilin-1 binds isoforms VEGF-165 and VEGF-145. Isoform VEGF165B binds to KDR but does not activate downstream signaling pathways, does not activate angiogenesis and inhibits tumor growth. Binding to NRP1 receptor initiates a signaling pathway needed for motor neuron axon guidance and cell body migration, including for the caudal migration of facial motor neurons from rhombomere 4 to rhombomere 6 during embryonic development.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eSubcellular Location\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eSecreted. Note=VEGF121 is acidic and freely secreted. VEGF165 is more basic, has heparin-binding properties and, although a significant proportion remains cell-associated, most is freely secreted. VEGF189 is very basic, it is cell-associated after secretion and is bound avidly by heparin and the extracellular matrix, although it may be released as a soluble form by heparin, heparinase or plasmin.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eProtein Family\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003ePDGF\/VEGF growth factor family\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eAssociated Diseases\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eMicrovascular complications of diabetes 1 (MVCD1)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eTissue Specificity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eIsoform VEGF189, isoform VEGF165 and isoform VEGF121 are widely expressed. Isoform VEGF206 and isoform VEGF145 are not widely expressed. A higher level expression seen in pituitary tumors as compared to the pituitary gland.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"100ug","offer_id":46701207814369,"sku":"BLT-03900P","price":556.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/files\/1gsg7rbknheo12fdj.jpg?v=1753344843"},{"product_id":"recombinant-human-vegf-a-vegf121-vegfa-protein-blt-04532p","title":"Human VEGFA (Vascular Endothelial Growth Factor A, Long Form) - Recombinant Protein","description":"\u003cmeta charset=\"utf-8\"\u003e\n\u003ch3 class=\"font_9\"\u003e\n\u003cmeta charset=\"utf-8\"\u003e\n\u003cspan\u003eProduct Overview\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003ctable width=\"100%\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eProduct Name\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eRecombinant Human VEGF-A\/VEGF121 (VEGFA) Protein\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eProduct Overview\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eThis recombinant human VEGF-A\/VEGF121 (VEGFA) protein includes amino acids  of the target gene is expressed in HEK293 Cells.The protein is supplied in lyophilized form and formulated in phosphate buffered saline (pH7.4) containing 0.01% sarcosyl, 5% trehaloseprior to lyophilization.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Uniprot Id\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eP15692\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eRecommended Name\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eVascular endothelial growth factor A, long form\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eGene Name\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eVEGFA\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eSynonyms\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eVascular endothelial growth factor A;VEGF-A;Vascular permeability factor;VPF;VEGFA;VEGF\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eSpecies\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eHuman\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003ePredicted Molecular Mass\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003e15.1 kDa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression System\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eMammalian Cell\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003e\u0026gt;85%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eFormulation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eLyophilized\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eBuffer\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003ePhosphate buffered saline (pH7.4) containing 0.01% sarcosyl, 5%Trehalose\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage Condition\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003e1. Store at -20°C\/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C\/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C\/-80°C.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eReconstitution Instruction\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eBriefly centrifuged the vial prior to opening to bring the contents to the bottom. Reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg\/mL. It is recommended to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C\/-80°C. The default final concentration of glycerol is 50%.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eApplications\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003ePositive Control; Immunogen; SDS-PAGE; WB\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eResearch Area\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eCancer\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Function\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eGrowth factor active in angiogenesis, vasculogenesis and endothelial cell growth. Induces endothelial cell proliferation, promotes cell migration, inhibits apoptosis and induces permeabilization of blood vessels. Binds to the FLT1\/VEGFR1 and KDR\/VEGFR2 receptors, heparan sulfate and heparin. NRP1\/Neuropilin-1 binds isoforms VEGF-165 and VEGF-145. Isoform VEGF165B binds to KDR but does not activate downstream signaling pathways, does not activate angiogenesis and inhibits tumor growth. Binding to NRP1 receptor initiates a signaling pathway needed for motor neuron axon guidance and cell body migration, including for the caudal migration of facial motor neurons from rhombomere 4 to rhombomere 6 during embryonic development.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eSubcellular Location\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eSecreted. Note=VEGF121 is acidic and freely secreted. VEGF165 is more basic, has heparin-binding properties and, although a significant proportion remains cell-associated, most is freely secreted. VEGF189 is very basic, it is cell-associated after secretion and is bound avidly by heparin and the extracellular matrix, although it may be released as a soluble form by heparin, heparinase or plasmin.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eProtein Family\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003ePDGF\/VEGF growth factor family\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eAssociated Diseases\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eMicrovascular complications of diabetes 1 (MVCD1)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eTissue Specificity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eIsoform VEGF189, isoform VEGF165 and isoform VEGF121 are widely expressed. Isoform VEGF206 and isoform VEGF145 are not widely expressed. A higher level expression seen in pituitary tumors as compared to the pituitary gland.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"100ug","offer_id":46701318930657,"sku":"BLT-04532P","price":556.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/files\/1gsgdvgtkabj6knj.jpg?v=1753347552"},{"product_id":"recombinant-mouse-vegf-a-vegf164-vegfa-protein-blt-05292p","title":"Mouse Vegfa (Vascular Endothelial Growth Factor A, Long Form) - Recombinant Protein","description":"\u003cmeta charset=\"utf-8\"\u003e\n\u003ch3 class=\"font_9\"\u003e\n\u003cmeta charset=\"utf-8\"\u003e\n\u003cspan\u003eProduct Overview\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003ctable width=\"100%\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eProduct Name\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eRecombinant Mouse VEGF-A\/VEGF164 (Vegfa) Protein\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eProduct Overview\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eThis recombinant mouse VEGF-A\/VEGF164 (Vegfa) protein includes amino acids 27-190aa of the target gene is expressed in P.pastoris.The protein is supplied in lyophilized form and formulated in phosphate buffered saline (pH7.4) containing 0.01% sarcosyl, 5% trehaloseprior to lyophilization.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Uniprot Id\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eQ00731\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eRecommended Name\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eVascular endothelial growth factor A, long form\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eGene Name\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eVegfa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eSynonyms\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eVascular endothelial growth factor A; VEGF-A; Vascular permeability factor; VPF; VEGFA; VEGFA164; VE\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eSpecies\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eMouse\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003ePredicted Molecular Mass\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003e19.3 kDa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression System\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eYeast\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression Range\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003e27-190aa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003e\u0026gt;90%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eFormulation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eLyophilized\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eBuffer\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003ePhosphate buffered saline (pH7.4) containing 0.01% sarcosyl, 5%Trehalose\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage Condition\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003e1. Store at -20°C\/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C\/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C\/-80°C.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eReconstitution Instruction\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eBriefly centrifuged the vial prior to opening to bring the contents to the bottom. Reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg\/mL. It is recommended to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C\/-80°C. The default final concentration of glycerol is 50%.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eApplications\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003ePositive Control; Immunogen; SDS-PAGE; WB\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"100ug","offer_id":46701529759969,"sku":"BLT-05292P","price":556.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/files\/1gsggle7g10hi5a4j.jpg?v=1753350774"},{"product_id":"recombinant-human-vegfa-protein-blt-05701p","title":"Human VEGFA (Vascular Endothelial Growth Factor A, Long Form) - Recombinant Protein","description":"\u003cmeta charset=\"utf-8\"\u003e\n\u003ch3 class=\"font_9\"\u003e\n\u003cmeta charset=\"utf-8\"\u003e\n\u003cspan\u003eProduct Overview\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003ctable width=\"100%\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eProduct Name\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eRecombinant Human \/ Cynomolgus VEGF \/ VEGFA \/ VEGF165 Protein\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eProduct Overview\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eThis recombinant human \/ Cynomolgus VEGF \/ VEGFA \/ VEGF165 protein includes amino acids 1-191aa of the target gene is expressed in HEK293 Cells.The protein is supplied in lyophilized form and formulated in phosphate buffered saline (pH7.4) containing 0.01% sarcosyl, 5% trehaloseprior to lyophilization.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Uniprot Id\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eP15692\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eRecommended Name\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eVascular endothelial growth factor A, long form\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eGene Name\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eVEGFA\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eSynonyms\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eMVCD1;VEGF;VEGF165;VPF\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eSpecies\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eHuman\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003ePredicted Molecular Mass\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003e19.2 kDa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression System\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eMammalian Cell\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression Range\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003e1-191aa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003e\u0026gt;90%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eFormulation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eLyophilized\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eBuffer\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003ePhosphate buffered saline (pH7.4) containing 0.01% sarcosyl, 5%Trehalose\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage Condition\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003e1. Store at -20°C\/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C\/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C\/-80°C.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eReconstitution Instruction\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eBriefly centrifuged the vial prior to opening to bring the contents to the bottom. Reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg\/mL. It is recommended to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C\/-80°C. The default final concentration of glycerol is 50%.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eApplications\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003ePositive Control; Immunogen; SDS-PAGE; WB\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eResearch Area\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eCancer\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Function\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eGrowth factor active in angiogenesis, vasculogenesis and endothelial cell growth. Induces endothelial cell proliferation, promotes cell migration, inhibits apoptosis and induces permeabilization of blood vessels. Binds to the FLT1\/VEGFR1 and KDR\/VEGFR2 receptors, heparan sulfate and heparin. NRP1\/Neuropilin-1 binds isoforms VEGF-165 and VEGF-145. Isoform VEGF165B binds to KDR but does not activate downstream signaling pathways, does not activate angiogenesis and inhibits tumor growth. Binding to NRP1 receptor initiates a signaling pathway needed for motor neuron axon guidance and cell body migration, including for the caudal migration of facial motor neurons from rhombomere 4 to rhombomere 6 during embryonic development.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eSubcellular Location\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eSecreted. Note=VEGF121 is acidic and freely secreted. VEGF165 is more basic, has heparin-binding properties and, although a significant proportion remains cell-associated, most is freely secreted. VEGF189 is very basic, it is cell-associated after secretion and is bound avidly by heparin and the extracellular matrix, although it may be released as a soluble form by heparin, heparinase or plasmin.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eProtein Family\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003ePDGF\/VEGF growth factor family\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eAssociated Diseases\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eMicrovascular complications of diabetes 1 (MVCD1)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eTissue Specificity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eIsoform VEGF189, isoform VEGF165 and isoform VEGF121 are widely expressed. Isoform VEGF206 and isoform VEGF145 are not widely expressed. A higher level expression seen in pituitary tumors as compared to the pituitary gland.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"100ug","offer_id":46701614924001,"sku":"BLT-05701P","price":556.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/files\/1gsdpf1fa11j91kkdj.jpg?v=1753352532"},{"product_id":"recombinant-human-vegfa-protein-blt-07194p","title":"Human VEGFA (Vascular Endothelial Growth Factor A, Long Form) - Recombinant Protein","description":"\u003cmeta charset=\"utf-8\"\u003e\n\u003ch3 class=\"font_9\"\u003e\n\u003cmeta charset=\"utf-8\"\u003e\n\u003cspan\u003eProduct Overview\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003ctable width=\"100%\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eProduct Name\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eRecombinant Human Vascular Endothelial Growth Factor A (VEGFA) Protein\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eProduct Overview\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eThis recombinant human Vascular Endothelial Growth Factor A (VEGFA) protein includes amino acids 28-147aa of the target gene is expressed in E.coli.The protein is supplied in lyophilized form and formulated in PBSprior to lyophilization.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Uniprot Id\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eP15692\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eRecommended Name\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eVascular endothelial growth factor A, long form\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eGene Name\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eVEGFA\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eSynonyms\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eVEGF; VEGF-A; VPF; Vascular Endothelial Cell Growth Factor A; Vascular Permeability Factor\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eSpecies\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eHuman\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003ePredicted Molecular Mass\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003e17\u0026amp;18 kDa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression System\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eE.coli\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression Range\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003e28-147aa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eTag\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eN-6His\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003e\u0026gt;95%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eFormulation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eLyophilized\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eBuffer\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003ePBS\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage Condition\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003e1. Store at -20°C\/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C\/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C\/-80°C.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eReconstitution Instruction\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eBriefly centrifuged the vial prior to opening to bring the contents to the bottom. Reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg\/mL. It is recommended to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C\/-80°C. The default final concentration of glycerol is 50%.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eApplications\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003ePositive Control; Immunogen; SDS-PAGE; WB\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eResearch Area\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eCancer\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Function\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eGrowth factor active in angiogenesis, vasculogenesis and endothelial cell growth. Induces endothelial cell proliferation, promotes cell migration, inhibits apoptosis and induces permeabilization of blood vessels. Binds to the FLT1\/VEGFR1 and KDR\/VEGFR2 receptors, heparan sulfate and heparin. NRP1\/Neuropilin-1 binds isoforms VEGF-165 and VEGF-145. Isoform VEGF165B binds to KDR but does not activate downstream signaling pathways, does not activate angiogenesis and inhibits tumor growth. Binding to NRP1 receptor initiates a signaling pathway needed for motor neuron axon guidance and cell body migration, including for the caudal migration of facial motor neurons from rhombomere 4 to rhombomere 6 during embryonic development.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eSubcellular Location\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eSecreted. Note=VEGF121 is acidic and freely secreted. VEGF165 is more basic, has heparin-binding properties and, although a significant proportion remains cell-associated, most is freely secreted. VEGF189 is very basic, it is cell-associated after secretion and is bound avidly by heparin and the extracellular matrix, although it may be released as a soluble form by heparin, heparinase or plasmin.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eProtein Family\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003ePDGF\/VEGF growth factor family\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eAssociated Diseases\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eMicrovascular complications of diabetes 1 (MVCD1)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eTissue Specificity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eIsoform VEGF189, isoform VEGF165 and isoform VEGF121 are widely expressed. Isoform VEGF206 and isoform VEGF145 are not widely expressed. A higher level expression seen in pituitary tumors as compared to the pituitary gland.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"100ug","offer_id":46701858259169,"sku":"BLT-07194P","price":556.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/files\/1h779bsen1c7b156qj.jpg?v=1753358770"},{"product_id":"recombinant-human-vegf165-vegfa-protein-blt-07571p","title":"Human VEGFA (Vascular Endothelial Growth Factor A, Long Form) - Recombinant Protein","description":"\u003cmeta charset=\"utf-8\"\u003e\n\u003ch3 class=\"font_9\"\u003e\n\u003cmeta charset=\"utf-8\"\u003e\n\u003cspan\u003eProduct Overview\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003ctable width=\"100%\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eProduct Name\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eRecombinant Human VEGF165 (VEGFA) Protein\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eProduct Overview\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eThis recombinant human VEGF165 (VEGFA) protein includes amino acids 28-191aa of the target gene is expressed in E.coli.The protein is supplied in lyophilized form and formulated in PBSprior to lyophilization.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Uniprot Id\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eP15692\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eRecommended Name\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eVascular endothelial growth factor A, long form\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eGene Name\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eVEGFA\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eSynonyms\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eVEGF\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eSpecies\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eHuman\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003ePredicted Molecular Mass\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003e19 kDa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression System\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eE.coli\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression Range\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003e28-191aa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eTag\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eN-6His\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003e\u0026gt;90%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eFormulation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eLyophilized\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eBuffer\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003ePBS\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage Condition\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003e1. Store at -20°C\/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C\/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C\/-80°C.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eReconstitution Instruction\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eBriefly centrifuged the vial prior to opening to bring the contents to the bottom. Reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg\/mL. It is recommended to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C\/-80°C. The default final concentration of glycerol is 50%.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eApplications\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003ePositive Control; Immunogen; SDS-PAGE; WB\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eResearch Area\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eCancer\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Function\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eGrowth factor active in angiogenesis, vasculogenesis and endothelial cell growth. Induces endothelial cell proliferation, promotes cell migration, inhibits apoptosis and induces permeabilization of blood vessels. Binds to the FLT1\/VEGFR1 and KDR\/VEGFR2 receptors, heparan sulfate and heparin. NRP1\/Neuropilin-1 binds isoforms VEGF-165 and VEGF-145. Isoform VEGF165B binds to KDR but does not activate downstream signaling pathways, does not activate angiogenesis and inhibits tumor growth. Binding to NRP1 receptor initiates a signaling pathway needed for motor neuron axon guidance and cell body migration, including for the caudal migration of facial motor neurons from rhombomere 4 to rhombomere 6 during embryonic development.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eSubcellular Location\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eSecreted. Note=VEGF121 is acidic and freely secreted. VEGF165 is more basic, has heparin-binding properties and, although a significant proportion remains cell-associated, most is freely secreted. VEGF189 is very basic, it is cell-associated after secretion and is bound avidly by heparin and the extracellular matrix, although it may be released as a soluble form by heparin, heparinase or plasmin.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eProtein Family\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003ePDGF\/VEGF growth factor family\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eAssociated Diseases\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eMicrovascular complications of diabetes 1 (MVCD1)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eTissue Specificity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eIsoform VEGF189, isoform VEGF165 and isoform VEGF121 are widely expressed. Isoform VEGF206 and isoform VEGF145 are not widely expressed. A higher level expression seen in pituitary tumors as compared to the pituitary gland.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"100ug","offer_id":46702007714017,"sku":"BLT-07571P","price":556.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/files\/1hqr1o8p1cne11bpj.jpg?v=1753360397"},{"product_id":"recombinant-mouse-vegfa-protein-blt-07921p","title":"Mouse Vegfa (Vascular Endothelial Growth Factor A, Long Form) - Recombinant Protein","description":"\u003cmeta charset=\"utf-8\"\u003e\n\u003ch3 class=\"font_9\"\u003e\n\u003cmeta charset=\"utf-8\"\u003e\n\u003cspan\u003eProduct Overview\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003ctable width=\"100%\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eProduct Name\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eRecombinant Mouse Vascular Endothelial Growth Factor A (VEGFA) Protein\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eProduct Overview\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eThis recombinant mouse Vascular Endothelial Growth Factor A (VEGFA) protein includes amino acids 27-190aa of the target gene is expressed in 293F cell.The protein is supplied in lyophilized form and formulated in PBSprior to lyophilization.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Uniprot Id\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eQ00731\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eRecommended Name\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eVascular endothelial growth factor A, long form\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eGene Name\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eVegfa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eSynonyms\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eVEGF; VEGF-A; VPF; Vascular Endothelial Cell Growth Factor A; Vascular Permeability Factor；VEGF164\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eSpecies\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eMouse\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003ePredicted Molecular Mass\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003e30 kDa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression System\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eMammalian Cell\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression Range\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003e27-190aa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eTag\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eN-6His\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003e\u0026gt;90%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eFormulation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eLyophilized\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eBuffer\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003ePBS\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage Condition\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003e1. Store at -20°C\/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C\/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C\/-80°C.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eReconstitution Instruction\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eBriefly centrifuged the vial prior to opening to bring the contents to the bottom. Reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg\/mL. It is recommended to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C\/-80°C. The default final concentration of glycerol is 50%.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eApplications\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003ePositive Control; Immunogen; SDS-PAGE; WB\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"100ug","offer_id":46702184038625,"sku":"BLT-07921P","price":556.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/files\/1i81h349kfgmp4j.jpg?v=1753361941"},{"product_id":"recombinant-mouse-vegfa-protein-blt-07985p","title":"Mouse Vegfa (Vascular Endothelial Growth Factor A, Long Form) - Recombinant Protein","description":"\u003cmeta charset=\"utf-8\"\u003e\n\u003ch3 class=\"font_9\"\u003e\n\u003cmeta charset=\"utf-8\"\u003e\n\u003cspan\u003eProduct Overview\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003ctable width=\"100%\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eProduct Name\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eRecombinant Mouse Vascular Endothelial Growth Factor 165 (VEGF165\/Vegfa) Protein\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eProduct Overview\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eThis recombinant mouse Vascular Endothelial Growth Factor 165 (VEGF165\/Vegfa) protein includes amino acids 26-190aa of the target gene is expressed in E.coli.The protein is supplied in lyophilized form and formulated in PBS, pH7.4, 5% Trehalose.prior to lyophilization.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Uniprot Id\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eQ00731\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eRecommended Name\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eVascular endothelial growth factor A, long form\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eGene Name\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eVegfa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eSpecies\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eMouse\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003ePredicted Molecular Mass\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003e20 kDa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression System\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eE.coli\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression Range\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003e26-190aa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eTag\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eN-His\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003e\u0026gt;90%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eFormulation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eLyophilized\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eBuffer\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003ePBS, pH7.4, 5% Trehalose.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage Condition\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003e1. Store at -20°C\/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C\/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C\/-80°C.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eReconstitution Instruction\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eBriefly centrifuged the vial prior to opening to bring the contents to the bottom. Reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg\/mL. It is recommended to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C\/-80°C. The default final concentration of glycerol is 50%.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eApplications\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003ePositive Control; Immunogen; SDS-PAGE; WB\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"100ug","offer_id":46702220312801,"sku":"BLT-07985P","price":556.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/files\/1i9sjd1d2fms1bebj.png?v=1753362238"},{"product_id":"recombinant-human-vegf-165-protein-active-low-endo-bep-0028ul","title":"Recombinant Human VEGF 165 Protein, Active, Low Endotoxin","description":"\u003cmeta charset=\"utf-8\"\u003e\n\u003ch3 class=\"font_9\"\u003e\n\u003cmeta charset=\"utf-8\"\u003e\n\u003cspan\u003eProduct Overview\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003ctable width=\"100%\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eProduct Name\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eRecombinant Human VEGF 165 Protein\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Symbol\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eVEGFA\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eAlternative Names\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eVascular Endothelial Growth Factor, VEGF-A, Vascular Permeability Factor, VPF, MVCD1\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eAccession Number\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eP15692\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression System\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eE. coli. Disulfide-linked homodimer\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eMolecular Weight\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003e19.2 kDa (monomer, predicted)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eSequence\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eAla27-Arg191\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003e\u0026gt;98% by SDS-PAGE and quantitative densitometry by Coomassie® Blue staining.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eActivity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eDetermined by a cell proliferation assay using HUVEC human umbilical vein endothelial cells.\nThe ED50 for this effect is typically 1-5 ng\/mL.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eFormulation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eLyophilized from sterile HEPES and NaCl with Trehalose, pH 7.4\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eEndotoxin Level\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003e\u0026lt;0.001 EU\/1ug (\u0026lt;1 EU\/mg) of the protein as determined by the LAL method.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eShipping\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eShipped at ambient temperature.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eStability \u0026amp; Storage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003e12 months from date of receipt at -20°C to -70°C, lyophilized powder.\n3 months at -20°C to -70°C under sterile conditions after reconstitution.\nAvoid repeated freeze-thaw cycles.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eReconstitution\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eReconstitute at 100 ug\/mL in sterile PBS.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Function\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eVascular endothelial growth factor (VEGF) is involved in angiogenesis, vasculogenesis, neurogenesis and endothelial cell growth during embryonic development and in adults. It induces endothelial cell proliferation, migration, and permeabilization of blood vessels. VEGF is upregulated during hypoxia, inflammation, tissue repair and during neovascularization of tumors and adipose tissue. Additionally, VEGF induces neural progenitor cell proliferation and regulates mesenchymal stem cell differentiation. VEGF binds to the VEGFR1 (FLT1) and VEGFR2 (KDR\/CD309) receptors, however, Neuropilin-1 will also bind VEGF as a coreceptor for VEGFR2.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eTissue Specificity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eVEGF expression has been reported in vascular endothelial cells, ovaries, adipose tissue, skeletal muscle and most tumors.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eCellular Localization\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eSecreted protein\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eInvolvement In Disease\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eVEGF dysregulation is implicated in macular degeneration, diabetic retinopathy, rheumatoid arthritis, psoriasis, and cancer.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"100ug","offer_id":48253309681889,"sku":"BEP-0028UL","price":974.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/files\/EXRP021-SDSPAGE-01.jpg?v=1777340526"}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/collections\/Protein_CD47_PDB_2JJS_e223487e-b235-4ba7-abe6-61e66f9a6498.png?v=1778549802","url":"https:\/\/www.betalifesci.com\/collections\/vegfa-protein-overview-applications-selection-guide.oembed","provider":"Beta LifeScience","version":"1.0","type":"link"}